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1 .INTRODUCTION
The oral route currently represents the most predominant and preferable route
of  drug  delivery.  Unlike  majority  of  parenteral  dosage  forms,  it  allows  ease  of
administration by the patient, and therefore a highly convenient way for substances to
be introduced into the human body. Oral drug delivery systems have progressed from
conventional immediate release to site-specific delivery over a period of time. Every
patient would always like to have an ideal drug delivery system possessing the two
main properties that are single dose or less frequent dosing for the whole duration of
treatment and the dosage form must release active drug directly at the site of action.
1.1      CONVENTIONAL DRUG DELIVERY SYSTEM
Oral drug delivery is the most widely utilized route of administration among
all  the  routes  that  have  been  explored  for  systemic  delivery  of  drugs  via
pharmaceutical products of different dosage forms.
The oral dosage form has survived due to
1. Relatively simple and inexpensive to make
2. Convenient for the patient
3. Technology is easy to adapt to changing needs of the drug substance
4. Simplifies the regulatory approval process.
Pharmaceutical  products designed for oral  delivery are mainly conventional
drug  delivery  systems,  which  are  designed  for  immediate  release  of  drug  for
rapid/immediate absorption (Robinson JR Lee, 1987).
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As can be seen from Figure 1, administration of the conventional dosage form
by extra vascular  route does not maintain the drug level in blood for  an extended
period of time. The short duration of action is due to the inability of conventional
dosage form to control temporal delivery. 
Figure 1: Hypothetical plasma concentration-time profile from conventional multiple
dosing and single doses of sustained and controlled delivery formulations. (MSC =
maximum safe concentration, MEC = minimum effective concentration).
Limitations of the Conventional Drug Delivery System:
1) Drugs  with  short  half-life  require  frequent  administration,  which  increases
chances of missing the dose of drug leading to poor patient compliance.
2) A typical peak-valley plasma concentration-time profile is obtained which makes
attainment of steady state condition difficult. 
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3) The  unavoidable  fluctuations  in  the  drug  concentration  may  lead  to  under
medication or overmedication as the steady state concentration values fall or rise
beyond the therapeutic range. 
4) The fluctuating drug levels may lead to precipitation of adverse effects especially
of a drug with small therapeutic index, whenever overdosing occurs. 
In order to overcome the drawbacks of conventional drug delivery systems,
several  technical  advancements  have  led  to  the  development  of  controlled  drug
delivery system that could revolutionize method of medication and provide a number
of therapeutic benefits (Chien, 1992).
1.2    CONTROLLED DRUG DELIVERY SYSTEM (CDDS)
Over the years, as the expense and complications involved in marketing, new
drug  entities  have  increased  with  concomitant  recognition  of  the  therapeutic
advantages  of  controlled drug delivery.  Greater  attention has been focused  on the
development of modified release dosage forms.
Modified  release  systems  have  been  developed  to  improve  the
pharmacokinetic  profiles  of  active  pharmaceutical  ingredients  (APIs)  and  patient
compliance, as well as reducing side effects. Oral modified release delivery systems
are most commonly used for 1) delayed release (e.g., by using an enteric coating); 2)
extended release (e.g., zero-order, first-order, biphasic release, etc.); 3) programmed
release (e.g., pulsatile, triggered, etc.) and 4) site specific or timed release (e.g., for
colonic delivery or gastric retention). Extended, sustained or prolonged release drug
delivery systems are terms used synonymously to describe this group of controlled
drug  delivery  devices,  with  predictability  and  reproducibility  in  the  drug  release
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kinetics.  Delayed release dosage forms are distinguished from the ones mentioned
above as they exhibit a pronounced lag time before the drug is released. Oral extended
release dosage forms offer the opportunity to provide constant or nearly constant drug
plasma levels over  an extended period of time following administration.  Extended
release DDS include single-unit, such as tablets or capsules, and multiple-unit dosage
forms, such as minitablets, pellets, beads or granules, either as coated (reservoir) or
matrix devices.
Controlled Release
Controlled  release  systems  are  designed  to  maintain  plasma  levels  in
therapeutic  range  and  thus  minimize  the  effects  of  such  problems.  Furthermore,
controlled release systems reduce  the dosing frequency,  thereby improving patient
compliance and therapeutic efficacy (Christopher et al., 2005).
Sustained Release
Drug products that provide “extended” or “sustained” drug release appeared as
a  major  class  of  dosage  form.  Many terms  as  sustained-release,  sustained-action,
prolonged- action, controlled-release, extended-release, timed-release, and long-acting
have been used to describe product types and features. For the most part, these terms
are  used  to  describe  orally  administered  dosage  forms,  whereas  the  term  rate-
controlled delivery is applied to certain types of drug delivery systems in which the
rate  of  drug  delivery  is  controlled  by  features  of  the  device  rather  than  by
physiological or environmental conditions as gastrointestinal pH or drug transit time
through the gastro intestinal tract (GIT).
Modified-release,  this  term  has  come into  general  use  to  describe  dosage  forms
having  drug  release  features  based  on  time,  course,  and/or  location  which  are
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designed  to  accomplish  therapeutic  or  convenience  objectives  not  offered  by
conventional or immediate-release forms.
Extended-release,  defines  an  extended-release  dosage  form as  one  that  allows  a
reduction in dosing frequency to that presented by a conventional dosage form.
Delayed-release dosage form is designed to release the drug from the dosage form at
a time other than promptly after administration. The delay may be time- based or
based on the influence of environmental conditions, as gastrointestinal pH.
Controlled drug delivery systems (CDDS) offer several advantages compared to
conventional DDS including: 
Avoiding  drug  level  fluctuations  by  maintenance  of  optimal  therapeutic
plasma and tissue concentrations over prolonged time periods, avoiding sub-
therapeutic as well as toxic concentrations, thus minimizing the risk of failure
of the medical treatment and undesirable side effects; 
Reducing the administered dose while achieving comparable effects; 
Reduced frequency of administration leading to improved patients compliance
and subsequently improved efficacy of the therapy and cost effectiveness; 
Targeting or timing of the drug action. Hence, it is highly desirable to develop
CDDS releasing the drug at predetermined rates to achieve optimal drug levels
at the site of action. 
Disadvantages of CDDS 
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• Unpredictable or poor in vitro- in vivo correlation.
• Dose dumping.
• Reduced potential for dosage adjustment.
• Increased first pass clearance
• Poor systemic availability in general
• High cost.
An orally  administered  controlled  drug  delivery system encounters  a  wide
range of highly variable conditions, such as pH, agitation intensity, and composition
of the gastrointestinal fluids as it passes down the G.I tract. Considerable efforts have
been  made  to  design  oral  controlled  drug  delivery  systems  that  produce  more
predictable and increased bioavailability of drugs. However, the development process
is precluded by several physiological difficulties, like inability to retain and localize
the drug delivery system within desired regions of the G.I tract and highly variable
nature of the gastric emptying process. The gastric emptying process can vary from a
few minutes to 12 h, depending upon the physiological state of the subject and the
design  of  pharmaceutical  formulation.  This  variation  may  lead  to  unpredictable
bioavailability and times to achieve peak plasma levels.  In  addition,  the relatively
brief  gastric  emptying  time in  humans,  through the  stomach or  upper  part  of  the
intestine (Major absorption zone), can result in incomplete drug release from the DDS
leading to diminished efficacy of the administered dose.
1.3 ABSORPTION WINDOW 
Some  drugs  display  region-specific  absorption  that  can  be  related  to
differential drug solubility and stability in different regions of the intestine as a result
of changes in environmental pH, degradation by enzymes present in the lumen of the
intestine or interaction with endogenous components such as bile. Active transport
mechanisms for drugs involving carriers and pump systems have been well described.
Dept. of pharmaceutics                           6                                J.K.K.M.M.R.F college of pharmacy
Chapter 01                                                                                                   Introduction
Compounds  such  as  ACE  inhibitors  and  certain  antibiotics  exploit  peptide
transporters. The importance of P-450 metabolism in the intestinal mucosa has now
been  recognized.  The  isoform  P4503A4  (CYP3A4)  is  dominant  in  ‘gut  wall’
metabolism and different  levels are found in different regions of the intestine. The
absorption  of  drugs  can  also  be  limited  by  efflux  mechanisms,  especially  if
compounds are lipophilic in nature. The secretory transporter P-glycoprotein located
on the  mucosal  surface  of  epithelial  cells  is  responsible  for  the low and  variable
bioavailability of various compounds (e.g.-propranolol, felodipine). Some drugs can
be substrate  for  both CYP3A4 and P-glycoprotein (cyclosporine,  itraconazole).  In
theory, it should be possible to inhibit efflux and metabolism processes by the use of
inhibitors, but such agents are not usually without their own pharmacological effects.
The inhibitory effect of grapefruit juice toward intestinal CYP450 is a well known
example.
Today, it is possible to assess regional differences in intestinal drug absorption
by  conducting  non-invasive  human  drug  absorption  (HDA)  study  using  a  remote
controlled delivery capsule. Gamma scintigraphy is used for real-time visualization of
capsule location and a radiofrequency signal  is used to activate the capsule at the
target site. For example, in order to determine the bioavailability and pharmacokinetic
profile of faropenem daloxate (a prodrug of broad spectrum antibiotic), this drug was
delivered in a particulate  form to the proximal small bowel,  distal small bowel or
ascending colon. The pharmacokinetic  profiles  for delivery to the two sites in the
small intestine were similar and comparable to those for a reference tablet. Significant
absorption was also seen after  delivery to the colon, but the area under the curve
(AUC) and the maximum plasma concentration (Cmax) values were markedly reduced.
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Concept of absorption window 
 Drug  exhibiting  absorption  from only  a  particular  portion  of  GI  tract  or
showing difference in absorption from various regions of GI tract are said to have
regional  variability  in  intestinal  absorption.  Such  drugs  show  absorption  window
which signifies the regions of GI tract from where absorption primarily occurs.  Drug
released from the CRDDS after the 
                Figure 2: a) Conventional drug delivery system, (b) GRDDS.
absorption window has  been crossed  goes  waste  with no or  negligible  absorption
occurring (Figure 2). This phenomenon drastically decreases the available drug for
absorption, after release of drug from CRDDS. The CRDDS possessing the ability of
being retained in the stomach are called GRDDS and they can help in optimizing the
oral controlled delivery of drugs having absorption window by continuously releasing
drug prior to absorption window, for prolonged period of time thus ensuring optimal
bioavailability. 
 This absorption window is observed due to following factors 
Physicochemical factors
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pH- dependent solubility and stability
A  drug  experiences  a  pH  range  of  1-8  across  the  G.I  tract  and  needs  to  be  in
solubilized form to successfully cross the biological membrane. Most of the drugs are
passively absorbed in their un-ionized form and the extent of ionization at different
pH values depends on solubility,  stability and ionization by changing the physical
properties  of  the  drug  in  different  portions  of  the  G.I  tract,  can  lead  to  regional
variability in absorption of drugs.
Physiological factors
(a) Mechanism of absorption
Perorally administered drugs are absorbed both by passive diffusion as well  as by
nonpassive means of absorption. Drugs absorbed by active and facilitated transport
mechanisms  show  higher  regional  specificity  due  to  the  prevalence  of  these
mechanisms only in a particular region of G.I tract.
(b) Metabolic Enzymes
Presence of certain enzymes in a particular region of G.I tract can also lead to
regional variability  in  absorption  of  drugs  that  are  substrates  to  those  enzymes.
Intestinal metabolic enzymes principally, phase I metabolizers like cytochrome P450
are  abundantly  present  in  the  intestinal  epithelium.  Their  activity  decreases
longitudinally  along  the  small  intestine,  with  the  levels  rising  slightly  from  the
duodenum to  the  jejunum and  then  declining  in  the  ileum  and  colon.  This  non-
uniform distribution of cytochrome P450 causes regional variability in the absorption
of drugs that are substrate to these enzymes.
1.4 GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS 
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Gastro-retentive dosage forms are drug delivery systems which remain in the
stomach for an extended period of time and allow both spatial and time control of
drug liberation. Basically, gastroretentive system retains in the stomach for a number
of  hours  and  continuously  releases  the  incorporated  drug  at  a  controlled  rate  to
preferred absorption sites in the upper intestinal tract. The retention of oral dosage
forms in the upper GIT causes prolonged contact time of drug with the GI mucosa,
leading  to  higher  bioavailability,  and  hence  therapeutic  efficacy,  reduced  time
intervals for  drug administration,  potentially reduced dose size and thus improved
patient  compliance.  Therefore,  Sustained  release  DDS possessing  gastric  retention
properties may be potentially useful.
1.4.1 ANATOMY AND PHYSIOLOGY OF THE GI TRACT
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Figure 3: Structure of the gastrointestinal tract
To  comprehend  the  considerations  taken  in  the  design  of  GRDFs  and  to
evaluate  their  performance  the  relevant  anatomy  and  physiology  of  the
gastrointestinal  tract  must  be  fully  understood.  The  basic  Structure  of  the
gastrointestinal tract is shown in Fig 3.
The GIT consists  of  a  hollow muscular  tube starting from the oral  cavity,
where food enters, the mouth, continuing through the pharynx, oesophagus, stomach
and intestines to the rectum and anus. Anatomical and physiological features of the
human GIT are given in Table 1.
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Table 1: Anatomical and physiological features of the human GIT
Section
Avg
length
(cm)
Diam
eter
(cm)
Villi
present
Absorption
mechanism
pH
Major
constituents
Transit
time  of
food (h)
Oral cavity 15-20 10 -
Passive  diffusion,
convective
transport
5.2-
6.8
Amylase,
Maltase,
Ptyalin, Mucins
Short
Esophagus 25 2.5 - - 5-6 -
Very
short
Stomach 20 15 -
Passive  diffusion,
convective
transport
1.2-
3.5
Hydrochloric
acid,  Pepsin,
rennin,  lipase,
intrinsic factor
0.25-3
Duodenum 25 5 +
Passive  diffusion,
convective
transport,  active
transport,
facilitated
transport, ion pair,
pinocytosis
4.6-6
Bile,  Trypsin,
chymo  trypsin,
amylase,
maltase,  lipase,
nuclease,  CYP
3A4
1-2
Jejunum 300 5 ++
Passive  diffusion,
convective
transport,  active
transport,
facilitated
transport
6.3-
7.3
Amylase,
maltase, lactase,
sucrose,  CYP
3A5
-
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Ileum 300 2.5-5 ++
Passive  diffusion,
convective
transport,  active
transport,
facilitated
transport
7.6
Lipase,
nuclease,
nucleotidase,ent
ro kinase
1-10
Cecum 10-30 7 +
Passive  diffusion,
convective
transport,  active
transport,
Pinocytosis
7.5-8 - Short
Colon 150 5 -
Passive  diffusion,
convective
transport,  active
transport
7.6-8 - 4-20
Rectum 15-19 2.5 -
Passive  diffusion,
convective
transport,  active
transport,
Pinocytosis
7.5-8 - Variable
Stomach
The stomach is  situated  in  the  left  upper  part  of  the  abdominal  cavity  under  the
diaphragm, between the lower end of the esophagus and the small intestine, and is the
most dilated part of the GIT. Its opening to the duodenum is controlled by the pyloric
sphincter. The stomach is divided into three anatomical regions (Figure 4).
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i) Fundus
ii) Body and
iii) Pylorus (or antrum)
               The proximal stomach consisted of fundus and body, which serves as a
reservoir for ingested materials, whereas the distal region (pylorus) is the major site of
mixing motions,  acting as a pump to propel  gastric  contents for gastric  emptying.
(Tortora et al., 1996; Wilson and Waugh, 1989).
Figure 4: Schematic illustration of the stomach anatomical structure.
Small Intestine
The small  intestine  is  composed  of  the  duodenum,  jejunum, and  ileum.  It
averages  approximately  6m  in  length.  The  duodenum  is  the  proximal  C-shaped
section that curves around the head of the pancreas. The duodenum serves a mixing
function  as  it  combines  digestive  secretions  from the  pancreas  and  liver  with  the
contents expelled from the stomach. The start of the jejunum is marked by a sharp
bend, the duodenojejunal flexure. It is in the jejunum where the majority of digestion
and  absorption  occurs.  The  final  portion,  the  ileum,  is  the  longest  segment  and
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empties into the caecum at the ileocaecal  junction. The small intestine has a large
surface area, which is comparable to the area of a basketball court, 463 m2. This is the
main reason it is the primary absorption site of water,  ions, vitamins and nutrients
such as amino acids, fats and sugars. In addition, the digestion of fats, peptides and
sugars  occurs  in  this  segment  of  the  gastrointestinal  tract.  The  pH  of  the  small
intestine is 6–7. The transit time in the small intestine is long, relatively constant and
is unaffected by food.
Large Intestine
The colon has some absorption properties of water and ions. Certain drugs and
especially peptide molecules are also absorbed. This is despite the lack of villi, which
leads to small surface area.
Gastric emptying
The time a dosage form takes to traverse the stomach is usually termed the
‘gastric emptying rate’. Gastric emptying of Pharmaceuticals is highly variable and is
dependent on dosage form. The process of gastric emptying occurs during fasting as
well as fed states. However, the pattern of motility is distinct in the 2 states. In the
fasting state, it  is  characterized by an interdigestive series of electrical  events that
cycle both through stomach and small intestine every 2 to 3 hours. This activity is
called the interdigestive myoelectric  cycle or migrating myoelectric cycle (MMC),
which is further divided into following 4 consecutive phases (Figure 5) as described
by Wilson and Washington.
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Figure 5: Motility patterns of the GIT in the fasted state.
• Phase I (Basal phase) lasts from 30 to 60 minutes with rare contractions.
• Phase II (Preburst phase) lasts for 20 to 40 minutes with intermittent action
potential and contractions. As the phase progresses the intensity and frequency
also increases gradually. 
• Phase III (Burst phase) lasts for 10 to 20 minutes. It  includes intense and
regular  contractions  for  short  period.  It  is  due  to  this  wave  that  all  the
undigested material is swept out of the stomach down to the small intestine. It
is also known as the housekeeper wave.
• Phase IV lasts for 0 to 5 minutes and occurs between phases III and I
of 2 consecutive cycles. 
The motor activity in the fed state is induced 5-10 min after ingestion of a meal
and persists as long as food remains in the stomach. It consists of regular and frequent
contractions. These contractions are not as severe as those in the third phase of the
fasted motility pattern. The G.I. Transit times of dosage forms in the various segments
of the G.I. tract are listed in Table 2.
Table 2: Transit times of various dosage forms across the segments of the GIT.
Dosage forms Transit time(h)Stomach Small intestine Total
Tablets 2.7±1.5 3.1±0.4 5.8
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Pellets 1.2±1.3 3.4±1.0 4.6
Capsules 0.8±1.2 3.2±0.8 4.0
Solution 0.3±0.07 4.1±0.5 4.4
Gastric pH 
The gastric pH is influenced by many factors like diet, disease, presence of
gases or fatty acids, and other fermentation products (Rubinstein, 1990), age (Varis et
al., 1979), pathological  conditions  drugs, as well as intra- and inter-subject variation.
This  variation  in  pH  may  significantly  influence  the  performance  of  orally
administered drugs. Radiotelemetry, a noninvasive device, has successfully been used
to measure the gastrointestinal pH in humans. It has been reported that the mean value
of gastric pH in fasted healthy males is 1.7 ± 0.3 (Chung et al., 1986; Dressman et al.,
1990; Russell et al., 1993), while that of females was reported to be slightly lower
(Charman et al., 1997; Feldman and Barnett, 1991). On the other hand, in the fed
state, the mean gastric pH in healthy males has been reported to be between 4.3 – 5.4
(Dressman et al., 1990), and the pH returned to basal level in about 2 to 4 hours. 
About 20% of the elderly people exhibit either diminished (hypochlorohydria)
or no gastric acid secretion (achlorohydia) leading to basal pH value over 5.0 (Varis et
al.,  1979).  Pathological  conditions  such  as  pernicious  anemia  and  AIDS  may
significantly reduce gastric acid secretion leading to elevated gastric pH (Holt et al.,
1989; Lake-Bakaar et al., 1988). In addition, drugs like H2 receptor antagonists and
proton pump inhibitors significantly reduce gastric acid secretion.
Hence,  the gastric  pH is an important  consideration when selecting a drug
substance, excipients, and drug carrier for designing intragastric delivery systems.
1.4.2 FACTORS AFFECTING GASTRIC RETENTION OF DOSAGE FORMS
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 Density: Gastric retention time (GRT) is a function of dosage form buoyancy
that is dependent on the density of a dosage form which affects the gastric
emptying rate. A buoyant dosage form should have a density of less than that
of the gastric  fluids floats.  Since it  is away from the pyloric  sphincter,  the
dosage unit is retained in the stomach for a prolonged period.
 Size: Dosage form units having a diameter of more than 7.5 mm are reported
to have  an increased  gastric  residence  time compared  with those  having a
diameter of 9.9 mm. Gastric retention time of a dosage form in the fed state
can also be influenced by its size. Small tablets are emptied from the stomach
during the digestive phase while large size units are expelled during the house
keeping waves.
 Shape of dosage form:  Different shapes (ring, tetrahedron, cloverleaf, disk,
string and pellet) displays different gastric retention times, due to their size
and  geometry  of  the  systems.  The  tetrahedron  resided  in  the  stomach  for
longer periods than other devices of a similar size; likewise extended gastric
retention was observed with rigid rings .Tetrahedron and ring-shaped devices
with a flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI) have
a better gastric residence time as compared with other shapes and had been
reported to have better (GRT 90% to 100% retention at 24 hours compared
with other shapes).
 Single or multiple unit formulation: Multiple unit formulations show a more
predictable release profile and insignificant impairing of performance due to
failure of units, allow co-administration of units with different release profiles
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or containing incompatible substances and permit a larger  margin of safety
against dosage form failure compared with single unit dosage forms.
 Fed or unfed state: Under fasting conditions, the GI motility is characterized
by  periods  of  strong  motor  activity  or  the  migrating  myoelectric  complex
(MMC)  that  occurs  every  1.5  to  2  hours.  The  MMC  sweeps  undigested
material  from  the  stomach  and,  if  the  timing  of  administration  of  the
formulation coincides  with that  of  the MMC, the GRT of  the unit  can  be
expected to be very short. However,  in the fed state,  MMC is delayed and
GRT is considerably longer. It was concluded that as meals were given at the
time when the previous digestive phase had not completed, the floating form
buoyant in the stomach could retain its position for another digestive phase as
it was carried by the peristaltic waves in the upper part of the stomach.
 Nature  of  meal:  Feeding  of  indigestible  polymers  or  fatty  acid  salts  can
change the motility pattern of the stomach to a fed state, thus decreasing the
gastric emptying rate and prolonging drug release. (Timmermans et al, 1994)
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is
high in proteins and fats. (Marvola et al., 1989).  
 Frequency  of  feed: The  GRT  can  increase  by  over  400  minutes,  when
successive  meals  are  given  compared  with  a  single  meal  due  to  the  low
frequency of MMC. 
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 Gender:  Mean ambulatory GRT in males (3.4 ± 0.6 hours) is less compared
with  their  age  and  race  matched  female  counterparts  (4.6  ±  1.2  hours),
regardless of the weight, height and   body surface. 
 Age:  Elderly  people,  especially  those  over  70,  have  a  significantly  longer
GRT. 
 Posture: GRT can vary between supine and upright ambulatory states of the
patient. 
 Concomitant  drug  administration:  Anticholinergics  like  atropine  and
Propantheline,  opiates  like  codeine  and  prokinetic  agents  like
Metoclopramide and Cisapride (Mojave Ian et al., 1988) can affect the gastric
retention time.
 Biological  factors: Diabetes  and  Crohn’s  disease  can  affect  the  gastric
retention time.
1.4.3   DRUG CANDIDATES FOR GASTRIC RETENTION 
Gastroretentive  DDSs  exhibiting  controlled  drug  release  are  significantly
important for drugs which are: 
 Acting  locally  in  the  stomach  (e.g.  antibiotics  against  Helicobacter  Pylori,
antacids and Misoprostol) (Burton et al., 1995; Fabregas et al., 1994; Oth et
al., 1992; Whitehead et al., 2000; Whitehead et al., 1996). 
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 Absorbed incompletely due to a relatively narrow window of absorption in the
GIT,  such  as  Cyclosporin,  Ciprofloxacin,  Furosemide,  L-DOPA,  P-
aminobenzoic acid and Riboflavin (Drewe et al., 1992; Erni and Held, 1987;
Harder et al., 1990; Hoffman et al., 2004; Ichikawa et al., 1991a; Klausner et
al., 2003d; Levy and Jusko, 1966; Rouge et al., 1996). 
 Unstable in the intestinal or colonic environment such as Captopril (Matharu
and Sanghavi, 1992) or 
 Exhibit low solubility at high pH values such as Verapamil HCl, Diazepam
and Chlordiazepoxide (Chen and Hao, 1998; Elkheshen et al., 2004; Sheth and
Tossounian, 1984; Soppimath et al., 2001). 
In general the group of drugs, that benefits from an oral application using a
gastroretentive  DDS,  includes  analgesics,  antibiotics,  tranquilizers,  diuretics,
antidepressants, vitamins, hormones, antacids and antiparkinsonian drugs (Hoichman
et al., 2004). 
Gastroretentive DDS, on the other hand, are not suitable for drugs that may
cause gastric lesions, e.g., non-steroidal anti-inflammatory agents and drug substances
that  are  unstable  in  the  strong  acidic  environment  of  the  stomach.  In  addition,
gastroretentive systems do not offer significant advantages over conventional dosage
forms for drugs, which are absorbed throughout the gastrointestinal tract (Talukder
and  Fassihi,  2004).  It  is  recognized,  however,  that  there  are  many  physiological
constraints which may limit development of such delivery systems. 
1.4.4    APPROACHES TO GASTRIC RETENTION
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Various approaches have been pursued to increase the retention of oral dosage
forms in  the stomach.  The most  common approaches  used to  increase  the  gastric
residence time of pharmaceutical dosage forms include
 Floating systems
 Swelling and expanding systems
 Bioadhesive systems
 Unfolding and modified- shape systems
 High density systems
 Others
1.4.4.1 Floating Systems
Floating drug delivery systems (FDDS) have a bulk density less than gastric
fluids and so remain buoyant in the stomach without affecting the gastric emptying
rate  for  a  prolonged  period  of  time.  While  the  system  is  floating  on  the  gastric
contents (mechanism given in Figure 6), the drug is released slowly at the desired rate
from  the  system.  After  release  of  drug,  the  residual  system is  emptied  from  the
stomach. This results in an increased 
Figure 6: Mechanism of floating systems
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GRT and a better control of the fluctuations in plasma drug concentration. However,
besides  a  minimal  gastric  content  needed  to  allow the  proper  achievement  of  the
buoyancy retention principle, a minimal level of floating force (F) is also required to
keep the dosage form reliably buoyant on the surface of the meal.
Most floating systems reported in the literature are single unit systems, such as
HBS and floating tablets. The systems are unreliable and irreproducible in prolonging
residence time in the stomach when orally administered due to their all or nothing
empting process (Kawashima et al., 1991). On the other hand, multiple unit dosage
forms, such as hollow microsphere (microballoons), granules, powder, and pellets, are
more suitable since they are claimed to reduce the inter- and intra-subject variability
in absorption and reduce the probability of dose dumping (Rouge et al., 1997).
Types of floating drug delivery systems   (FDDS)
Floating properties based on the mechanism of buoyancy are divided into:
1. Non effervescent systems with inherent low density due to swelling; and
2. Effervescent systems with low density due to gas generation and entrapment. 
1.4.4.1.1 Non- Effervescent Systems
A) Hydrodynamically Balanced Systems
These are single-unit dosage forms, containing one or more gel-forming hydrophilic
polymers.  The polymer  is  mixed with drug  and  usually  administered  in  a  gelatin
capsule. The capsule rapidly dissolves in the gastric fluid, and hydration and swelling
of the surface polymers produces a floating mass. Drug release is controlled by the
formation of a hydrated boundary at the surface (Dubernet et al., 2004). Continuous
erosion of the surface allows water penetration to the inner layers, maintaining surface
hydration and buoyancy (Reddy et al.,2002)(Figure7).
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Figure 7: Hydrodynamically balanced system
Hydrodynamically balanced systems (HBS) are designed to prolong the stay
of the dosage form in the gastro intestinal tract and aid in enhancing the absorption.
Such systems are best suited for drugs having a better solubility in acidic environment
and also for the drugs having specific site of absorption in the upper part of the small
intestine. To remain in the stomach for a prolonged period of time the dosage form
must have a bulk density of less than 1. It should stay in the stomach, maintain its
structural integrity, and release drug constantly from the dosage form. The success of
HBS  capsule  as  a  better  system  is  best  exemplified  with  chlordiazeopoxide
hydrochloride.  The drug is  a  classical  example of  a  solubility problem wherein  it
exhibits a 4000-fold difference in solubility going from pH 3 to 6 (the solubility of
chlordiazepoxide hydrochloride is  150 mg/mL at  acidic pH and is  ~0.1 mg/mL at
neutral pH).
B) Alginate Beads
Multi-unit  floating  dosage  forms  have  been  developed  from  freeze-dried
calcium  alginate.  Spherical  beads  of  approximately  2.5  mm  in  diameter  can  be
prepared  by  dropping  sodium  alginate  solution  into  aqueous  solution  of  calcium
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chloride, causing the precipitation of calcium alginate. The beads are then separated,
snap-frozen in liquid nitrogen, and freeze-dried at -40ºC for 24 hours, leading to the
formation of a porous system, which can maintain a floating force for over 12 hours.
These floating beads gave a prolonged residence time of more than 5.5 hours.
C) Hollow Microspheres / Microballons:
Hollow  microspheres  loaded  with  drug  in  their  outer  polymer  shelf  were
prepared by a novel emulsion solvent diffusion method. The ethanol/dichloromethane
solution  of  the  drug  and  an  enteric  acrylic  polymer  was  poured  into  an  agitated
solution of Poly Vinyl Alcohol (PVA) that was thermally controlled at 40ºC. The gas
phase  is  generated  in  the  dispersed  polymer  droplet  by  the  evaporation  of
dichloromethane. The microballoon floated continuously over the surface of an acidic
dissolution  media  containing  surfactant  for  more  than  12  h in  vitro  (Kawashima,
1992).
Floating microparticles based on low-density foam powder has been proposed
and  its  performance  investigated  in  vitro  (Streubel  et  al.,  2002).  The  floating
microparticles  were  prepared  with  an  oil-in-water  solvent  extraction/evaporation
method and were composed of polypropylene foam powder;  verapamil HCl as the
model  drug;  and  a  controlled  release  polymer,  Eudragit®  RS,  EC or  polymethyl
methacrylate (PMMA). The microparticles were irregular in shape and highly porous.
Good  in  vitro  floating  behavior  was  observed.  The  increase  in  drug  release  was
proportional to the drug loading and inversely proportional to the amount of polymer
and the release profile varied with varying the polymer type.
1.4.4.1.2 Effervescent Systems (Gas-Generating Systems):
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This approach provides floating drug delivery systems based on the formation
of  CO2 gas.  It  utilizes  effervescent  components  such  as  sodium  bicarbonate
(NaHCO3) or sodium carbonate,  and additionally citric or tartaric acid (Rubinstein
and Friend, 1994). Alternatively matrices containing chambers of liquids that gasify at
body temperature could be used. Upon contact with the acidic environment, a gas is
liberated,  which produces an upward motion of the dosage form and maintains its
buoyancy. A decrease in specific gravity causes the dosage form to float on gastric
contents.
These buoyant systems utilize matrices prepared with swellable polymers such
as  methocel,  polysaccharides  (e.g.,  chitosan),  and  effervescent  components  (e.g.,
sodium bicarbonate, citric acid or tartaric acid).The system is so prepared that upon
arrival in the stomach, carbon dioxide is released, causing the formulation to float in
the stomach. Other approaches and materials that have been reported are a mixture of
sodium alginate  and sodium bicarbonate,  multiple  unit  floating pills  that  generate
carbon  dioxide  when  ingested,  floating  minicapsules  with  a  core  of  sodium
bicarbonate,  lactose  and  polyvinylpyrrolidone  coated  with  hydroxypropyl
methylcellulose  (HPMC),  and  floating  systems  based  on  ion  exchange  resin
technology, etc. (Rubinstein A et al., 1994; Stockwell AF et al., 1986). 
Ichikawa  et  al developed  a  new  multiple  type  of  floating  dosage  system
composed of effervescent layers and swellable membrane layers coated on sustained
release pills. The inner layer  of effervescent agents containing sodium bicarbonate
and tartaric acid was divided into 2 sublayers to avoid direct contact between the 2
agents.  These  sublayers  were  surrounded  by  a  swellable  polymer  membrane
containing polyvinyl acetate and purified shellac. When this system was immersed in
Dept. of pharmaceutics                           26                                J.K.K.M.M.R.F college of 
pharmacy
Chapter 01                                                                                                   Introduction
the buffer at 37ºC, it settled down and the solution permeated into the effervescent
layer through the outer swellable membrane. CO2 was generated by the neutralization
reaction between the 2 effervescent agents,  producing swollen pills (like balloons)
with a density less than 1.0 g/ml.  It  was found that  the system had good floating
ability, independent of pH and viscosity and the drug released in a sustained manner
(Figure 8).
Figure  8:  (a)  A  multi-unit  oral  floating  dosage  system.  (b)  Stages  of  floating
mechanism:  (A)  penetration  of  water;  (B)  generation  of  CO2 and  floating;  (C)
Dissolution of drug.
Table 3: List of drugs prepared as FDDS
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S.No. DOSAGE FORM DRUGS
1. Microspheres
Metformin  hydrochloride,  ketoprofen,  Aspirin,
Verapamil, Grisiofulvin, P-nitroanilline, Ibuprofen,
2. Granules Diclofenac sodium, Indomethacin, Prednisolone
3. Capsules
Chlordiazepoxide HCl,  Diazepam, Frusemide,  L-Dopa
and  Benserazide, Misoprostol, Propranolol
4. Tablets/Pills Phenytoin hydrochloride,5 fluoro uracil, Furosemide,.
TABLE 4: LIST OF DRUGS WHICH ARE MARKETED AS FDDS
Brand name Drug Clinical Importance Dosage form
Madopar®
Levodopa
Benserazide
Parkinsonism Capsule
Cytotec® Misoprostal Gastric ulcer Capsule
Valrelease® Diazepam Sedative –hypnotic Capsule
Conviron Ferrous sulphate Pernicious anemia Capsule
Liquid Gavison®
Al. hydroxide,
Mg. carbonate
Heart burn
Liquid  alginate
preparation
Topalkan® Al-Mg antacid Antacid
Liquid  alginate
preparation
Cifran OD® Ciprofloxacin Urinary tract infection Tablet
Oflin OD® Ofloxacin
Genital  Urinary,
respiratory,  Gastro-
intestinal infection
Tablet
Prolopa® Propranolol Hypertension Tablet
Amalgate
Flotacoat®
Amalgate Antacid Tablet
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HaloTM Propranolol Hypertension Tablet
Raft-Forming Systems
Here,  a  gel-forming  solution  (e.g.  sodium  alginate  solution  containing
carbonates  or  bicarbonates)  swells  and  forms  a  viscous  cohesive  gel  containing
entrapped CO2 bubbles (Figure 9) on contact  with gastric  fluid.  Formulations also
typically  contain  antacids  such  as  aluminium  hydroxide  or  calcium  carbonate  to
reduce gastric acidity.  Because raft-forming systems produce a layer on the top of
gastric fluids, they are often used for gastroesophageal reflux treatment.
Figure 9: Schematic illustration of the barrier formed by a raft-forming system
Low-density systems
1.4.4.2   Swelling and Expanding Systems
A dosage form in the stomach will withstand gastric transit if it is bigger than the
pyloric sphincter (Caldwell et al., 1988). However,  the dosage form must be small
enough to be swallowed, and must not cause gastric obstruction either singly or by
accumulation. Thus, three configurations are required, a small configuration for oral
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intake, an expanded gastroretentive form and a final small form enabling evacuation
following drug release.
The expansion of this type of DDS is generally due to the presence of specific
hydrogel formers, which after swallowing; drastically increase in size upon contact
with  aqueous  media.  This  increase  in  size  prevents  their  exit  from  the  stomach
through the pylorus. As a result, the dosage form is retained in the stomach for a long
period of time. These systems may be referred to as the  “plug type systems” since
they exhibit a tendency to remain lodged at the pyloric sphincter. Caldwell et al., 1988
proposed different geometric forms (tetrahedron, ring or planar membrane (4-lobed,
disc or 4-limbed cross form) of biodegradable polymer compressed within a capsule.
1.4.4.3 Bioadhesive Systems
This approach is used to localize a delivery device within the lumen and cavity
of  the  body to  enhance  the  drug  absorption  process  in  a  site-specific  manner.  A
bioadhesive can be defined as a substance with the ability to interact with biological
materials and is capable of being retained on the biological substrate for a period of
time. Bioadhesion always occurs in the presence of water (Andrews et al., 2009).
It involves the use of bioadhesive polymers that can adhere to the epithelial
surface of the GIT. These are usually macromolecular, hydrophilic gelling substances
with numerous hydrogen-bond forming groups,  such as carboxyl,  hydroxyl,  amide
and  sulfate  groups  (e.g.,  crosslinked  polyacrylic  acids,  sodium  carboxymethyl
cellulose (CMC), sodium alginate and carrageenan). A broad spectrum of polymers
was studied for their bioadhesive properties. It was concluded that anionic polymers
have better binding capacity than neutral or cationic polymers (Lehr, 1994;Gupta et
al., 1990). The proposed mechanism of bioadhesion is the formation of hydrogen –
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and  electrostatic  bonding  at  the  mucus-polymer  boundary  (Gupta  et  al.,  1990),
although  it  is  not  yet  clear.  Rapid  hydration  in  contact  with  the  muco-epithelial
surface appears to favour adhesion.
1.4.4.4 Unfolding and Modified- Shape Systems
These  are  non  disintegrating  geometric  shapes  moulded  from  silastic
elastomer or extruded from polyethylene blends, which extend the gastric residence
time  depending  on  size,  shape  and  flexural  modulus  of  the  drug  delivery  device
(Caldwell, 1988a, 1988c; Cargill et al., 1988; Fix et al., 1993; Kedzierewicz et al.,
1999). 
 These systems consist of at least one erodible polymer (e.g., Eudragit® E,
hydroxypropyl  cellulose  (HPC)),  one  nonerodible  polymer  (e.g.,  polyamides,
polyolefins,  polyurethanes),  and  a  drug  dispersed  within  the  polymer  matrix.
Cloverleaf, disk, string and pellet shapes were moulded from silastic elastomer, while
tetrahedron  and  rigid-ring  shapes  were  fabricated  from  blends  of  low-density
polyethylene and ethylene: vinyl acetate copolymer. The devices are compressible to
a size suitable for swallowing within a capsule,  and are self-expandable to a size,
which prevents their passage through the pylorus. Furthermore, they are sufficiently
resistant to forces of the stomach to prevent rapid passage through the pylorus for a
pre-determined period of time, and erode in the presence of gastric juices.
In  vivo  studies  in  beagle  dogs  have  been  performed  to  study  the  systems
physical  characteristics,  such as size, shape and flexibility on the gastric emptying
(Cargill  et  al.,  1988),  after  they were folded and placed in a  gelatin  capsule.  The
tetrahedron-shaped devices remained in the stomach for longer periods of time than
the other shapes, while strings and pellets were eliminated fairly rapidly. 
Dept. of pharmaceutics                           31                                J.K.K.M.M.R.F college of 
pharmacy
Chapter 01                                                                                                   Introduction
Other shapes, which can be packed into gelatin capsules and increase in size
following unfolding, include Y-shaped systems (Sonobe, 1995) and sheet-like shaped
devices (Brewer, 1980).
1.4.4.5 High Density Systems
Sedimentation has been employed as a retention mechanism for pellets that are
small enough to be retained in the rugae or folds of the stomach body near the pyloric
region, which is the part of the organ with the lowest position in an upright posture.
Dense pellets (approximately 3g/cm-3) trapped in rugae also tend to withstand the
peristaltic movements of the stomach wall. With pellets, the GI transit time can be
extended from an average of 5.8–25 hours, depending more on density than on the
diameter of the pellets. Commonly used excipients are barium sulphate, zinc oxide,
titanium dioxide and iro powder, etc. These materials increase density by up to 1.5–
2.4g/cm-3 (Bechgaard H, et al.,1978).
1.4.4.6 Magnetic Systems
This system is  based on a simple idea:  The dosage  form contains  a  small
internal  magnet  and  a  magnet  placed  on  the  abdomen  over  the  position  of  the
stomach. Ito et al., 1990 used this technique in the rabbits with bioadhesive granules
containing ultra fine Ferrite (γ-Fe2O3). This guided them to the esophagus with an
external  magnet  (~1700 G) for  the initial  2 min and almost all  the granules  were
retained in the region after 2 hrs. Fujmori et al., 1994 formulated a magnetic tablet
containing 50% w/w ultra ferrite with hydroylpropylcellulose and Cinnarazine.
1.4.5    ADVANTAGES  OF  GASTRORETENTIVE  DRUG  DELIVERY
SYSTEM
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Floating  drug  delivery  offers  several  applications  for  drugs  having  poor
bioavailability because  of  the  narrow absorption window in the upper  part  of  the
gastrointestinal  tract.  It  retains the dosage forms at the site of absorption and thus
enhances the Bioavailability. These are summarized as follows.
I. Sustained Drug Delivery
Sustained drug absorption from oral controlled release dosage form is often
limited due to short gastric retention time. However, GFDDS remain in the stomach
for several hours to their increased GRT. It has been suggested that due to their low
density than their gastric contents and relatively large size they do not pass through
the pylorus that has an opening of approximately 0.9-1.9cm. It has been observed that
major portion of drug releases in the colon rather than the stomach in case of modified
release  capsule.  However,  prolongation  in  the  GRT may sustain  the  drug .release
behaviour.
II. Site Specific Drug Delivery
Drugs having absorption sites in the upper small intestine like furosemide and
riboflavin are typically formulated in the floating dosage forms. It has been reported
that  absorption  of  furosemide  takes  place  mainly  through  stomach  followed  by
duodenum.  This  characteristics  of  furosemide  prompted  scientists  to  develop  a
monolithic floating system, which could prolong the GRT and thereby increase the
Bioavailability.  GFDDS  serves  as  an  excellent  drug  delivery  system  for  the
eradication of  Helicobacter pylori, which causes chronic gastritis and peptic ulcers.
The  treatment  requires  high  drug  concentrations  to  be  maintained  at  the  site  of
infection  that  is  within  the  gastric  mucosa.  By virtue  of  its  floating  ability  these
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dosage forms can be retained in the gastric region for a prolonged period so that the
drug can be targeted.
A  bilayer-floating  capsule  has  been  developed  for  local  delivery  of
misoprostol  to the gastric  mucosa for  prevention of gastric  ulcers  caused  by non-
steroidal  anti-inflammatory drugs  (NSAIDs).  Mechanistically,  the drug replenishes
the GI-protective prostaglandins that are depleted by NSAIDs. Therefore, sustained
and  controlled  delivery  of  misoprostol  to  the  stomach  provides  sufficient  local
therapeutic levels. This in turn reduces the side effects caused by the presence of the
drug in systematic circulation (uterotonic activity) and also retards diarrhoea, which is
the result of combination of intestinal and systematic exposure of drug. Moreover, the
prolonged gastric availability of the misoprostol from FDDS also reduces the dosing
frequency. 5-Fluorouracil bearing floating tablets have been successfully evaluated in
four patients with stomach neoplasms.
III. Absorption or Bioavailability Enhancement
Drugs that have poor Bioavailability because of site-specific absorption from
the upper part of the gastrointestinal tract are potential candidates to be formulated as
floating drug delivery systems,  thereby maximizing their  absorption. A significant
increase in the Bioavailability of floating dosage forms could be achieved.
IV. Fewer Doses: Creating once daily formulations for improved patient compliance.
V. Improved plasma levels: Both extends plasma concentration levels and provides a
more linear release profile.
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VI.  Better  Bioavailability:  Delivers  the  drug  in  the  upper  G.I.  tract  for  optimal
absorption.
VII. Less Irritation: The polymer matrix acts as a buffer between harsh drug crystals
and the stomach lining.
VIII. Fewer side effects: Keeps drugs out of the lower GI tract which can be harmful
to  intestinal  flora.  Lower  peak  concentrations  can  also  reduce  adverse
pharmacological effects.
IX.  Low  risk  inactive  ingredients:  Tablets  are  composed  of  well  .understood
polymers from the FDA.s inactive ingredients list. This keeps the regulatory risks and
hurdles of the formulation to an absolute minimum.
X.  Manufacturing  ease:  Tablets  are  made  in  standard  high-speed  tableting
equipment. No special tooling or engineering is required. The enables high quality,
consistent, rapid scale-up and technology transfer to our development and marketing
partners.
XI. Low cost: The ingredients used in these systems are commodity items, produced
in extremely large quantity and at very low cost.
1.4.6    DISADVANTAGES  OF  GASTRORETENTIVE  DRUG  DELIVERY
SYSTEM
Dept. of pharmaceutics                           35                                J.K.K.M.M.R.F college of 
pharmacy
Chapter 01                                                                                                   Introduction
1. There are certain situations where gastric retention is not desirable. Aspirin
and non-steroidal anti-inflammatory drugs are known to cause gastric lesions
and slow release of such drugs in the stomach is unwanted.
2. Thus, drugs that may irritate the stomach lining or are unstable in its acidic
environment should not be formulated in gastroretentive systems.
3. Furthermore,  other  drugs,  such  as  isosorbide  dinitrate,  that  are  absorbed
equally well throughout the GI tract will not benefit from incorporation into a
gastric retention system (Hou et al., 2003).
4. Gastric retention is influenced by many factors such as gastric motility,  pH
and  presence  of  food.  These  factors  are  never  constant  and  hence  the
buoyancy cannot be predicted exactly or accurately.
5. Gastric emptying of floating forms in supine subjects may occur at random
and become highly dependent on the diameter. Therefore, patients should not
be dosed with floating forms just before going to bed. 
6. High  variability  in  gastric  emptying  time  due  to  variations  in  emptying
process.
7. Unpredictable bioavailability.
1.4.7    LIMITATIONS
1. The major disadvantage of floating systems is requirement of a sufficiently
high level of fluids in the stomach for the drug delivery i.e. upto 400ml of
gastric  fluids  should  be  present  for  optimum  buoyancy.  However,  this
limitation  can  be  overcome  by  coating  the  dosage  form with  bioadhesive
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polymers, which easily adhere to the mucosal lining of the stomach and retain.
The dosage form can be administered with a glass full of water (200-250 ml)
to provide the initial fluid for buoyancy.
2. Floating system is not feasible for those drugs that have solubility problems in
gastric fluids.
3. Drugs  that  are  not  stable  at  gastric  pH  are  not  suitable  candidates  to  be
formulated as GRDDS.
4. Drugs  that  irritate  the  mucosa  are  not  suitable  candidates  and  should  be
avoided to be formulated as GRDDS.
5. The drugs, which have multiple absorption sites in the gastrointestinal tract
and are absorbed throughout gastrointestinal tract, which under significant first
pass metabolism, are not desirable candidates.
6. Some drugs present in the floating system cause irritation to gastric mucosa.
7. Single  unit  floating  capsules  or  tablets  are  associated  with  an  all  or  none
concept, but this can be overcome by formulating multiple unit systems like
floating microspheres or microballoons.
1.4.8    EVALUATION OF GRDDS
Any drug product must be evaluated to ensure its performance characteristics
and  to  control  batch-to-batch  quality.  In  addition  to  routine  tests  for  general
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appearance, hardness, friability, drug content, weight variation, uniformity of content,
disintegration  time,  and  drug  release,  the  gastroretentive  performance  of  GRDDS
must be evaluated.
1.4.8.1 Floating Systems
Floating/buoyancy time: The test for buoyancy is usually determined in 900 mL of
simulated  gastric  (HCl/NaCl  with  0.02%  Tween  80,  pH  1.2)  or  intestinal  fluids
KH2PO4/NaOH buffer with 0.02% Tween 80, pH 7.4) maintained at 370C using the
USP dissolution apparatus. These fluids simulate the surface tension of human gastric
juice  (35–50  mN/m2).  The  amount  of  time  the  dosage  form  floats  is  termed  the
floating time. In the case of floating microparticles, the number of floating particles
and  the  time  during  which  they  remain  buoyant  on  the  test  solution  can  be
determined.  The floating process  depends  on the balance  between  the weight  and
volume  of  the  dosage  form.  An  increase  in  the  buoyancy  force  caused  by  the
increased  volume  causes  a  resultant  weight  increase  and  leads  to  dosage-form
flotation. 
Specific gravity:  The specific gravity of floating systems can be determined by the
displacement method, using benzene as a displacing medium.
1.4.8.2   Bio/Mucoadhesion Systems
Bioadhesive strength: The bioadhesive strength of a polymer can be determined by
measuring the force required to separate the polymer specimen sandwiched between
the layers of either an artificial (e.g., cellophane) or biological (e.g., rabbit stomach
tissue) membrane. This force can be measured by using a modified precision balance
or an automated texture analyzer.
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1.4.8.3   Swelling Systems
Weight gain and water uptake (WU): The swelling behaviour of a dosage unit can
be measured by studying its weight gain or WU. The study is done by immersing the
dosage form in simulated gastric fluid at 370C and determining these factors at regular
intervals. The dimensional changes can be measured in terms of the increase in tablet
diameter and/or thickness over time. WU is measured in terms of percent weight gain,
as given by the following equation
WU = (Wt _ W0) × 100/W0
In  which,  Wt and  W0 are  the  weights  of  the dosage  form at  time  t  and initially,
respectively.  Furthermore, the GRDDS should be evaluated for gastroretention and
drug-release behaviour.
 
1.4.9   METHODS TO ASSESS IN-VIVO GASTRO-RETENTION OF GRDDS
Unlike other formulations, the kinetics of transit of the GRDF along the GI
tract, and especially in determining its GRT are very important. It requires, in most
cases, an imaging technique that can locate the GRDF in vivo. The following methods
have been utilized so far to assess gastro-retentivity.
i) Magnetic Resonance Imaging 
Magnetic  resonance  imaging  (MRI)  is  a  noninvasive  technique  that  is  not
associated with radioactivity and allows observation of the total anatomical structure
in relatively high resolution. The visualization of the GI tract by MRI has to be further
improved by the administration of contrast media. For solid DFs, the incorporation of
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a super paramagnetic compound such as ferrous oxide enables their visualization by
MRI.  The  technique  is  safe  and  allows  obtaining  many  pictures  from  the  same
subject. 
ii) Radiology (X-ray)  
In this technique, a radio-opaque material has to be incorporated in the DF, and its
location  is  tracked  by  X-ray  pictures.  The  technique  is  used  to  evaluate
gastroretentivity of GRDFs and the disintegration rate of DFs  in vivo,  and also to
determine  the  esophageal  transit.  Although  it  is  considered  cheap  and  a  simple
method to use, its major disadvantage is the safety issue owing to repeated exposure
to X-ray that increase the risk for the volunteers. 
iii) γ- Scintigraphy 
Gamma  scintigraphy  relies  on  the  administration  of  a  DF  containing  a  small
amount of radioisotope, e.g., 152Sm, which is a gamma ray emitter with a relatively
short half-life. The isotope has to be incorporated into the GRDF in advance. Then, a
short time prior to the study, the formulation has to be irradiated in a neutron source
that  causes  it  to  emit  g  rays.  The  emitted  ray  can  be  imaged  using  a  ‘‘gamma
camera’’-a form of a scintillation counter, combined with a computer to process the
image, and thereby the DF can be tracked in the GI tract. This technique is elegant
and provides proper assessment of gastroretentivity in humans. 
iv) Gastroscopy 
Gastroscopy is commonly used for the diagnosis and monitoring of the GI tract.
This technique utilizes a fiber optic or video system and can be easily applied for
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monitoring and locating GRDFs in the stomach. However, it is too inconvenient to
conduct the procedure frequently in the same experiment for one subject. In human,
the  procedure  can  be  applied  with  or  without  slight  anesthesia  while  it  requires
complete anesthesia in dogs. 
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2.  LITERATURE REVIEW
Dennis  et al.  (1992) described a buoyant controlled release powder formulation, which
may be either filled into capsules or compressed into tablets. The formulation consisted
of a drug of basic character, a pH dependent polymer, sodium or potassium alginate, a pH
independent  hydrocolloid  gelling  agent  such  as  HPMC,  methylcellulose,  HPC  or  a
mixture of two or more,  and a binder.  The formulation was considered unique in the
sense that it released the drug at a controlled rate regardless of the pH of the environment,
being free of calcium ion and carbon dioxide (CO2) producing material, and had drug
release properties similar to a tablet of identical composition.
Yuasa et al. (1996) developed intragastric floating and sustained release granules
of Diclofenac sodium using a polymer solution of HPC-L grade and EC, and calcium
silicate as a floating carrier, which has a characteristically porous structure. The coated
granules acquired floating ability from the air trapped in the pores of calcium silicate
when they were coated with a polymer.
Whitehead  et  al.  (1996) developed multiple unit  floating freeze dried calcium
alginate beads. These beads maintained a positive floating force for over 12 hrs, and the
density measurement,  using a helium pycnometer,  was less than 1 g/cm. The  in vivo
behavior  of  this  system  compared  to  non-floating  multiple-unit  dosage  forms
manufactured from identical material have also been performed using γ-scintigraphy in
the fed state (Whitehead et al., 1998). Prolonged gastric residence times of over 5.5 h
were achieved for the floating formulations, while the non-floating beads displayed short
gastric residence times, with a mean onset emptying time of 1 hr.
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A glycerol monooleate (GMO) matrix was recently proposed as a gastroretentive
carrier system by  Kumar  et al.  (2004).  The GMO matrices were prepared by melting
GMO at 55°C in a water bath, adding the drug under stirring and pouring the molten
mass into cylindrical moulds. The GMO matrices significantly swelled in water and the
swollen mass floated at the surface after a certain lag time.
Floating tablets using the anionic exchange resin, cholestyramine, was described
by  Todd  et  al.  (1979).  The  directly  compressed  tablet  was  composed  of  granules
containing anhydrous cholestyramine, low viscosity grade alginic acid and/ or citric acid,
and sufficient sodium carbonate or bicarbonate mixtures thereof to neutralize the acidic
groups of the alginic and citric acids. After swallowing, the components will react with
the gastric acid to form a carbonated raft which then floats on the stomach contents.
Atyabi et al. (1996a & 1996b) developed a similar system using the ion exchange
resin  Dowex.  The  resin  beads  were  loaded  with  sodiumbicarbonate  and  theophylline
which were bound to the resin. The loaded resin beads were coated with a semipermeable
membrane to overcome rapid loss of CO2. After exposure to gastric media, exchange of
bicarbonate and chloride ions took place and lead to the formation of CO2, which was
trapped within the membrane, causing the particles to float. Gastric residence time was
substantially prolonged,  compared with a control,  when the system was given after  a
light, mainly liquid meal. Furthermore,  the system was capable of sustaining the drug
release.
Chitosan based sustained release floating tablets using a mixture of NaHCO3 and
citric acid has been investigated by  Inouye  et al.  (1988). Two types  of chitosan with
different degrees of deacetylation, chitosan H and L, and prednisolone as a model drug
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were  used  and  two  types  of  preparations  were  examined.  The  first  were  directly
compressed tablets using a mixture of sodium hydrogen carbonate and citric acid, while
the  second  was  composed  of  a  directly  compressed  layer  coated  with  chitosan  layer
enclosing CO2. Both formulations imparted quick buoyancy to the preparations, but the
drug release from the preparation using chitosan L was slower than that of chitosan H. In
a further study, the release properties were controlled by regulating the chitosan content
of  the granules,  or  the chitosan L  membrane  thickness  of  the laminated  preparations
(Inouye et al., 1989).
Double  layered  matrix  tablets  have  been  proposed  containing  an  effervescent
layer  loaded with carbonate and optionally citric acid,  using HPMC K4M and K15M
(Ingani et al., 1987) or mixture of HPMC K 4M and polyethylene oxide (PEO) (Fassihi,
1998; Yang et al., 1999; Yang and Fassihi, 1996) as gelling hydrocolloid and release
controlling polymer.  After  contact  with  acidic  aqueous  media,  CO2 is  generated  and
entrapped within the gelling hydrocolloid,  causing the system to float;  meanwhile the
drug was released in a sustained manner.
Floating  minitablets,  using  tartaric  acid,  NaHCO3  and  calcium  carbonate  as
effervescent  components  and  glyceryl  palmitostearate  as  meltable  binder,  have  been
developed by  Goole  et al.  (2008a & 2008b).  The system consisted of a 3 mm drug-
containing  gas-generating  core,  prepared  by  melt  granulation  and  subsequent
compression, and coated with a flexible polymeric membrane of Eudragit® RL 30 D. The
minitablets were able to float within 10 min and remained buoyant for more than 13 h,
independent of the pH. In addition, the drug release was sustained for more than 12h.
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Umezawa (1978) developed floating minicapsules with a diameter in the range of
0.1-2 mm and were consisting of a NaHCO3 core, which is coated with an inner HPMC
layer  and  an  outer  pepstatin  layer.  On  contact  with  gastric  acid,  carbon  dioxide  is
generated  within the  core  causing the particles  to  float.  Furthermore,  the release  and
action of pepstatin within the stomach was prolonged, and the pepsin activity in patients
with gastric and duodenal ulcers was suppressed..
Omidian et al. (2005 & 2006) developed superporous hydrogel hybrids, which
are prepared by crosslinking a water-soluble or water-dispersible polymer to the formed
superporous hydrogel. Examples for hybrid agents are polysaccharides, such as sodium
alginate, pectin, chitosan or synthetic water-soluble hydrophilic polymers, e.g. poly(vinyl
alcohol).  Unlike  superporous  hydrogels  and  superporous  hydrogel  composites,
superporous hydrogel hybrids are not easily breakable when stretched due to their highly
elastic  properties  in  the  swollen  state,  which  may  be  very  useful  for  developing
gastrointestinal DDS.
Jackson et al. (2000) observed extended gastric residence times of the positively
charged  ion-exchange resin  cholestyramine,  an anionic  resin,  due  to  adhering to  and
coating  of  the  gastric  mucosa.  On  the  other  hand,  the  oppositely  charged  cationic-
exchange  resin  Amberlite  IRP-69  did  not  possess  the  same  characteristics.  Such
behaviors lead to concluding that the surface charge of the resin might play a significant
role in mucoadhesion and subsequent retention.
Tetracycline–sucralfate complex was prepared under acidic conditions by Higo et
al. (2004) and its mucoadhesive properties both in vitro and in vivo were evaluated. The
complex  showed  excellent  mucoadhesive  properties,  where  higher  amounts  of  the
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complex were retained on the gastric mucosa compared with the physical  mixtures of
tetracycline and sucralfate.
Mucoadhesive  microspheres  containing  drug  and  Carbopol®  934P  have  been
developed, which were dispersed within a waxy matrix of polyglycerol  esters of fatty
acids. The microspheres were reported to prolong the GI residence of the drug after oral
administration, by adhering to the stomach mucosa in rats and Mongolian gerbils, which
was due to the hydration and swelling of the Carbopol in the microspheres on contact
with water (Yohko Akiyama and Nagahara, 1999).
The unfolding system, developed by  Klausner  et al.  (2002),  was composed of
multilayer, polymeric films based on a drug-containing shellac matrix as the inner layer,
with outer shielding layers on both sides composed of hydrolysed gelatin/ Eudragit S/
glycerine/ glutaraldehyde. The system was optionally framed with rigid polymeric strips
composed  of  L-poly(lactic  acid)/  ethylcellulose  (EC).  Such  dosage  forms  were
administered to beagle dogs, after placing them into gelatin capsules. The dimensions and
the mechanical properties of the films influenced the in vivo gastric retention behaviour.
Prolonged residence times and improved absorption properties could be achieved with
the model drug riboflavin using a ≥ 2.5 × 2.5 cm large device.
In  addition,  levodopa-containing  multilayer  films  were  investigated  in  beagle
dogs (Klausner et al., 2003a). The mean absorption time of the drug was significantly
extended when it was compared to non-gastroretentive controlled release particles and
oral  solutions.  The  performance  of  levodopa-containing,  multilayer  films  was  also
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studied in humans  (Klausner et  al.,  2003b),  and gastric  retention for  ≥  5 h could be
achieved, due to the rigidity and size of the dosage forms.
Watanabe  et  al.  (1976) developed a single-unit,  floating drug delivery system
having an inherent low density, consisting of a hollow core composed of an empty hard
gelatin  capsule,  polystyrene  foam or  pop rice  grain,  and subsequently,  coated with  a
subcoat  of  cellulose  acetate  phthalate,  and  an  outer  drug-containing  coating  of  EC/
HPMC.
Sheth and Toussounian (1978) developed a HBS capsule containing a mixture of
a drug and hydrocolloids. Upon contact with gastric fluids, the capsule shell dissolves
and the mixture swells and forms a gelatinous barrier thereby remaining buoyant in the
gastric  juice  for  an  extended  period  of  time.  The  same  authors  developed  sustained
release floating tablets of an active ingredient  and one or more hydrocolloids such as
methylcellulose, HPC, HPMC, HEC and sodium CMC, which upon contact with gastric
fluid provided a water impermeable colloidal gel barrier on the surface of tablets (Sheth,
1979a, 1979b).
Mitra (1984) described a multilayered, flexible, sheet like medicament device that
was buoyant in the gastric juice of the stomach and had sustained release characteristics.
The  device  consisted of  self  supporting carrier  film(s)  made up of  a  water  insoluble
polymer matrix with the drug dispersed there in, and a barrier film overlaying the carrier
film. The barrier film consisted of a water insoluble and a water and drug permeable
polymer or copolymer. Both films were sealed together along their periphery, in such a
way as to entrap a plurality of small air pockets, which imparted the laminated films their
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buoyancy. The time for buoyancy and the rate of drug release can be modulated by the
appropriate selection of the polymer matrix.
Ushimaru et al. (1987) developed sustained release capsules containing a mixture
of a drug, a cellulose derivative or starch derivative which forms a gel in water, and a
higher fatty acid glyceride or higher alcohol or a mixture thereof which is solid at room
temperature (RT), with an inherent density of < 1 g/cm3.
Desai  and  Bolton  (1993) developed  controlled  release  floating  moulded  gel
tablets of theophylline using agar and light mineral oil. The light mineral oil was essential
for the floating property of the tablet. Additionally, it served to prevent the air entrapped
within the gel matrix from escaping in the acidic environment of the stomach, due to its
hydrophobicity. However, the mechanism is not yet clear. In another study, these authors
developed a similar formulation without using oil.
A  multiple-unit  gastroretentive  DDS  which  contained  air  compartments  was
described by Iannuccelli et al. (1998). The units forming the system were composed of a
calcium alginate  core separated  by an air  compartment  from a membrane  of  calcium
alginate or calcium alginate/ polyvinyl  acetate (PVA). Floating  in vitro  and  in vivo  of
drug-free  systems  was  observed.  When  furosemide  was  incorporated  into  the  units
(Iannuccelli et al., 2000); only 20% of the dug was released after 8 h. Therefore, a solid
dispersion of furosemide/PVP was prepared to improve the drug release.
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                                    3. AIM AND PLAN OF WORK
                  The present work is to formulate floating tablet of Amoxicillin trihydrate
by direct  compression method and  to  carry out  the evaluation  for  the  formulated
tablets as per official standards. Helicobacter pylori exists in the gastric mucous layer
or epithelial cell surfaces. Thus, the concentration and resident time of amoxicillin
trihydrate in  stomach would be effective for  complete eradication of Helicobacter
pylori. Amoxycillin trihydrate is considered as a good candidate for incorporation in a
gastro-retentive dosage form due to its high solubility in the stomach pH compared to
its solubility in the small intestine pH.
So gastro-retentive drug delivery system is desirable to prolong the residence time of
the  dosage  form  in  the  stomach  or  upper  gastrointestinal  tract  until  the  drug  is
completely released from the system. In order to extend the gastrointestinal residence
period, a gastroretentive floating drug delivery system of amoxycillin trihydrate has
been developed.
To  design  and Develop  the  single  unit  floating  matrix  tablets  of  Amoxicillin
trihydrate  with  different  natural  and   synthetic  polymers  such has HPMC K4M,
HPMC K15M, HPMC K100M  by taking single polymer in the formulation.
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To evaluate the physicochemical characteristics of all formulations and to carryout in
vitro drug  release studies using USP XXIV apparatus.To select the best formulation
based on the above studies for stability studies.
 
3.1  PLAN OF WORK
1. Literature survey
2. Solubility studies of Amoxycillin trihydrate.
3. Determination of drug – excipient compatibility using FTIR studies.
4.  Plotting of calibration curves of Amoxycillin trihydrate in 0.1 N HCl (pH 1.2).
5. Formulation  of  floating  tablets  of  Amoxycillin  trihydrate  with  HPMC  K4M,
HPMC K15M, HPMC K100M, and Xanthan gum by direct compression method
by taking single polymer in the formulation.
6. Evaluation of pre-compression blend for Bulk density, Tapped density, Hausner
ratio,     % Compressibility index and Angle of repose. Evaluation of  floating
tablets  of  Amoxycillin  trihydrate  for  Weight  variation,  Thickness,  Hardness,
Friability, Drug content, Floating lag time and floating duration time.
7. In vitro drug release studies of prepared floating tablets in 0.1 N HCl (pH 1.2) by
using  USP  dissolution  apparatus,  rotating  paddle  type  and  selection  of  best
formulation.
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8. To fit the obtained data in various kinetic models & suggest a suitable mechanism
of drug release.
9. Stability studies.
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       MATERIALS AND METHODS
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4.1 MATERIALS
                      Table 5:  4.1.1 MATERIALS USED IN THE STUDY
Name of chemical Source
Amoxycillin trihydrate   Hetero labs
HPMC K4M Colorcon Asia Pvt. Limited
HPMC K15M Colorcon Asia Pvt. Limited
HPMC K100M Colorcon Asia Pvt. Limited
Xanthan gum ISP ,Hyd.
Polyvinyl Pyrrolidine(K90) ISP ,Hyd.
Microcrystalline
cellulose(PH102)
Hetero lab’s,  Hyderabad
Sodium bicarbonate Merck specialties Pvt. Limited
Magnesium stearate M/S Mohan lal dayaran & Co.,
Talc M/S Mohan lal dayaran & Co.,
Barium Sulphate Eskay fine Chemicals, Mumbai
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                      Table 6: 4.1.2 EQUIPMENT USED IN THE STUDY
Name of equipment Manufacturer
Digital balance AW 120, Shimadzu Corporation, Japan.
Tablet dissolution apparatus Electrolab, India
Compression Machine Riddhi, Ahmedabad, India
Roche Friabilator  Tab machines, Germany
Pfizer Hardness tester Cadmach, Ahmedabad, India
UV/Visible Spectrophotometer Elico, SL-159, India
Digimatic vernier callipers Mitutoyo Corporation, China
Mechanical shaker Remi equipments.
FT -IR Spectrophotometer Perkin Elmer, UK
                          
4.1.3 AMOXYCILLIN TRIHYDRATE PROFILE
Amoxycillin,  formerly  amoxycillin,  tormoxin (in  India),  amoxycillin (cilamox)  in
Australia,  abbreviated  amox,  is a moderate-spectrum, bacteriolytic,  β-lactam antibiotic
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used to treat bacterial infections caused by susceptible microorganisms. It is usually the
amoxycillin trihydrate of choice within the class because it is better absorbed, following
oral administration, than other β-lactam antibiotics. It is also a treatment for cystic acne.
Chemical  name:  (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(phydroxyphenyl)acetamido]-3,3-
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate.
Structure:
                      
Molecular formula     : C16H19N3O5S. 3H2O
Molecular weight       : 419.45. 
Physical form : White crystalline powder
Solubility : Highly soluble in 0.1N HCl (shows pH dependent solubility, 
decreasing  with  increasing  pH),  Slightly  soluble  in  water,  methanol  and  ethanol.
Practically insoluble in chloroform and ether.
Melting range           : 192-194 oC 
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PHARMACOKINETIC PARAMETERS 
Bioavailability : 80-90%
Protein binding  : 20%
Half-life  : 1.7hrs
Tmax : 1-2hrs
Cmax  
                                        
  :  5 µg/mL 
Dosage              : 250-575mg for every 8hrs 
Log P value                 :  0.75
Forms:  Various hydrated forms of amoxycillin, including monohydrate, dihydrate, and
trihydrate have been reported among which, the trihydrate is the most stable hydrated
form.
Absorption window: Upper part of GIT
Mechanism of  action:  Amoxycillin  acts  by inhibiting  the  synthesis  of  bacterial  cell
walls.  It  inhibits  cross-linkage  between  the  linear  peptidoglycan  polymer  chains  that
make up a major component of the cell walls of both Gram-positive and Gram-negative
bacteria.
4.1.4   POLYMER PROFILES
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a)  4.1.4.1  HYDROXY PROPYL METHYL CELLULOSE (HPMC) 
Non-proprietary names
JP: Hydroxypropylmethylcellulose                                       
BP: Hypromellose
Ph Eur:  Methylhydroxypropylcellulosum
USP:  Hypromellose
Chemical Name:  Cellulose, 2-hydroxypropyl methyl ether.
Synonyms: Methyl  Hydroxy  Propyl  Cellulose,  Propylene  Glycol  ether  of
methylcellulose, Methocel, Metolose, E464, Pharmacoat, Culminal MHPC.
Structural Formula:
OR
CH2OR
O
OO
O
O
OR
OR
OR
CH2OR
Where R is H, CH3 or CH3-CH(OH)-CH2
Physical and chemical properties
Molecular weight : 10,000 – 15, 00,000
Color : White to creamy-white 
Nature : Fibrous or granular powder
Odour : Odourless
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Taste : Tasteless
Density : 0.3-1.3 g/mL
Specific gravity : 1.26
Solubility: Soluble in cold water, practically insoluble in Chloroform, ethanol (95%) and
ether but soluble in mixture of ethanol and Dichloromethane.
Viscosity: HPMC-K4M-3,000-5600mPas, K15M:  12,000-21,000 mPas
K100M:   80,000-1, 20,000 mPas.
Melting point: Browns at 190-200°C, chars at 225-230°C, Glass transition temperature
is 170-180°C.
Functional  category:  Coating  agent,  film-forming,  rate-controlling  polymer  for
sustained  release,  stabilizing     agent,  suspending  agent,  tablet  binder,  viscosity-
increasing agent.
Applications:
 In oral products HPMC is primarily used as tablet binder, in film coating and as an
extended release tablet matrix. Concentration between 2-5% w/w may be used as a
binder in either wet or dry granulation process. High viscosity grade may be used to
retard the release of water-soluble amoxycillin trihydrate from a matrix.
 HPMC is widely used in oral and topical pharmaceutical formulations.
 Concentration of 0.45-1% w/w may be added as a thickening agent to vehicle for eye
drop and artificial tear solution.
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 HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard
contact lenses. It is widely used in cosmetics and food products. In addition, HPMC is
used  as  an emulsifier,  suspending  agent  and  stabilizing  agent  in  topical  gels  and
ointments.  As  a  protective  colloid,  it  can  prevent  droplets  and  particle  from
coalescing or agglomerating thus, inhibiting the formation of sediments.
Stability and storage: It is stable although it is slightly hygroscopic. The bulk material
should be stored in an airtight container in a cool and dry place. Increase in temperature
reduces the viscosity of the solution.
Safety:  It is generally regarded as a non-toxic and non-irritant material so it is widely
used in many oral and topical pharmaceutical formulations. Excessive consumption of
HPMC may have laxative effect (Rowe et al., 2003).
b) 4.1.4.2  XANTHAN GUM
Xanthan Gum is a high molecular anion polysaccharide produced by fermentation of a
carbohydrate  with  Xanthomnonas  campestris.  It  is  completely  soluble  in  cold  or  hot
water.
Structure:
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Molecular formula: C35H49O29 (monomer)
Physical and chemical properties
Color : white to creamy-white, 
Nature : occurs as a fine, hygroscopic powder
Odour : odorless or almost odorless
Viscosity : > 1575 mPas
pH                               :           6.0-8.0
Solubility: Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and
water;  practically  insoluble  in  ether,  hydrocarbons,  and  mineral  oil.  In  water,  the
concentration of a solution is limited only by the viscosity of the resulting solution. 
Functional  Category: Used  in  Food,  Dietary  Supplements  and  Cosmetics,  as  a
thickening or gelling agent, stabilizer, emulsifier, and texturing agent.
Pharmaceutical Applications for Xanthan Gum 
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• Controlled/Sustained Release Tablets
• Antibiotic suspensions/sugar-free syrups
• “Slimming Aids”
• Preparations for Dysphagics
• Barium meals (X-ray contrast media).
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4.2   METHODS
4.2.1 CONSTRUCTION OF CALIBRATION CURVE:
4.2.1.1 Standard Graph of Amoxycillin Trihydrate in 0.1N HCl
The stock solution was freshly prepared by dissolving 100mg of  amoxycillin
trihydrate in 10ml of methanol in a 100mL volumetric  flask and then making up the
solution upto the mark using 0.1N HCl for obtaining the solution of strength 1000 µg/mL
(stock I).  From this stock 0.1, 0.5, 1, 1.5, 2.0, 3.0 and 3.5mL were taken separately and
made  up  to  10mL with  distilled  water,  to  produce  10,  50,  100,  150,  200,  300  and
350µg/mL respectively.  The absorbance  was measured  at  272nm using a UV-Visible
spectrophotometer  (Elico,  SD-159,  India) against  0.1  N  HCl  as  blank  and  plotted
graphically to give the standard graph of amoxycillin trihydrate. 
4.2.2 SOLUBILITY STUDY OF AMOXYCILLIN TRI HYDRATE:
Excess amount of amoxycillin trihydrate was placed in 0.1 N HCl in order  to
determine its solubility. The samples were shaken for 24 h at 37°C in a horizontal shaker.
The supernatant was filtered and the filtrate was diluted with 0.1N HCl and estimated by
UV/ Visible Spectrophotometer at λmax of 272 nm.
4.2.3  AMOXYCILLIN  TRIHYDRATE-EXCIPIENT  COMPATIBILITY
STUDIES:
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4.2.3.1 Fourier Transform Infrared (FTIR) Spectroscopy
The Fourier transform infrared (FTIR) spectra  of samples were obtained using
FTIR  spectrophotometer  (Perkin  Elmer).  Pure  amoxycillin  trihydrate,  individual
polymers and optimised formulations were subjected to FTIR study. About 2–3 mg of
sample was mixed with dried potassium bromide of equal weight and compressed to form
a KBr disk. The samples were scanned from 400 to 4000 cm−1.
4.2.4   EVALUATION OF FINAL BLEND:
The  final  blend  of  all  formulations  was  evaluated  for  Bulk  density,  Tapped
density, % Compressibility Index (CI), Hausner ratio and Angle of repose.
a) Bulk Density
30gms of material was passed through a sieve no. 25 to break up agglomerates
and introduced into a 100mL dry cylinder. Without compacting, the powder was carefully
levelled  and  the  unsettled  apparent  volume,  Vo,  was  read.  The  bulk  density  was
calculated, in grams per mL, using the formula (Shah et al., 1997).
Bulk density = (M) / (VO)
Where, M = Total mass of the material
b) Tapped Density 
After carrying out the procedure as given in the measurement of bulk density the
cylinder  containing  the  sample  was  tapped  using  a  mechanical  tapped  density  tester
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(Electrolab) that provides a fixed drop of 14±2 mm at a nominal rate of 300 drops per
minute. The cylinder was tapped 575 times initially followed by an additional tap of 750
times and then tapped volume Vf, was measured to the nearest graduated unit. The tapped
density was calculated, in g per mL, using the formula:
Tapped density = (M) / (Vf)
c) Measures of Powder Compressibility
The % Compressibility Index and Hausner Ratio are measures of the propensity
of a powder to be compressed. 
The Compressibility Index  (Carr’s  Index) is  a  measure  of  the propensity of a
powder to be compressed. It is determined from the bulk and tapped densities. In theory,
the less compressible a material the more flowable it is. As such, it is a measure of the
relative  inter-particulate  interactions.  In  a  free-flowing  powder,  such  interactions  are
generally less significant, and the bulk and tapped densities will be closer in value. For
poorer  flowing materials,  there are frequently greater  inter-particle interactions,  and a
greater  difference  between  the  bulk  and  tapped  densities  will  be  observed.  These
differences  are  reflected  in  the  Compressibility  Index  which  is  calculated  using  the
following formula:
% Compressibility Index =   (Vr-Vo) * 100 / Vr
                    Where, Vr = Tapped density 
                                Vo = Bulk density
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                                 Table 7: Compressibility index specifications
Compressibility Index Properties
5-12 Free flowing
12-16 Good
18-21 Fair
23-35 Poor
33-38 Very poor
>40 Extremely poor
Hausner Ratio
It indicates that the flow properties of the powder and measured by the ratio of
tapped density to bulk density.
Hausner ratio = Vo/ Vf
                             Vo = Bulk volume, Vr= Tapped volume
                                    Table 8: Hausner Ratio Specifications
Hausner Ratio Property
0 - 1.2 Free flowing
1.2 – 1.6 Cohesive powder
d) Angle of Repose
The fixed funnel method was employed to measure the angle of repose. A funnel
was secured with its tip at a given height ‘h’ above a graph paper that was placed on a flat
horizontal surface. The blend was carefully poured through the funnel until the apex of
the conical pile just touched the tip of the funnel. The radius, r of the base of the conical
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pile was measured. The angle of repose, α, was calculated using the following formula:
(Copper J, et al., 1986).
                                                Α = tan-1 h/r
4.2.5 FORMULATION DEVELOPMENT
4.2.5.1 Preparation of Single Unit Floating Matrix Tablets of AMT
Technology Applied: Direct compression.
The key ingredients included in the formulations are:
 Hydrophilic Polymers: HPMC K4M, HPMC K15M, HPMC K100M and Xanthan
gum to modify the pattern of amoxycillin trihydrate release from matrix.
 Effervescent agent: Sodium bicarbonate
 Filler: Micro Crystalline Cellulose
 Antiadherant: Talc
 Lubricant: Magnesium Stearate.
Accurately weighed quantities of polymer and MCC were taken in a mortar and
mixed geometrically,  to this required quantity of AMT was added and mixed slightly
with pestle. Accurately weighed quantity of Sodium bicarbonate was taken separately in
a mortar and powdered with pestle. The powder is passed through sieve no 40 and mixed
with the amoxycillin trihydrate blend which was also passed through sieve no 40. The
whole mixture was mixed for 3 minutes.  To this Magnesium stearate was added and
mixed  for   minutes,  later  Talc  was  added  and  mixed  for  2  minutes.  The  mixture
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equivalent to 850mg was compressed into tablets with 13.5mm capsulate punches at a
hardness of 6 kg/cm2.The composition of various formulations was given in Table 9(a-d)
                              Table 9a: Formulation trails with HPMC K4M 
                            
                                                 
                                  Total tablet weight: 850mg 
                         Table 9b: Formulation trails with HPMC K15M
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INGREDIENTS FORMULATIONS
Weight in mg F1 F2 F3
Amoxycillin
trihydrate 575 575 575
HPMC K4M 100 125 150
HPMC K15M - - -
HPMC K100M - - -
MCC 87 62 37
NaHCO3 72 72 72
Mg Stearate 8 8 8
Talc 8 8 8
INGREDIENTS
Weight in mg
FORMULATIONS
F4 F5 F6 F7
Amoxycillin
trihydrate
575 575 575 575
HPMC K4M - - - -
HPMC K15M 75 100 150 135
HPMC K100M - - - -
MCC 107 87 37 52
NaHCO3 72 72 72 72
Mg Stearate 8 8 8 8
Talc 8 8 8 8
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                                                 Total tablet weight: 850mg
                         
                           Table 9c: Formulation trails with HPMC K100M 
    
                                                Total tablet weight: 850mg
Table  9d:  Formulation  trials  with  combination  of  Xanthan  gum  (natural
polymer) and HPMC K100M (synthetic polymer)
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INGREDIENTS FORMULATIONS
Weight in mg F8 F9 F10
Amoxycillin
trihydrate
575 575 575
HPMC K4M - - -
HPMC K15M - - -
HPMC K100M 50 75 100
MCC 137 112 87
NaHCO3 72 72 72
Mg Stearate 8 8 8
Talc 8 8 8
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Ingredients (weights in
mg)
Formulations
F11 F12 F13
Amoxycillin trihydrate 575 575 575
Xanthan gum 50 30 30
HPMC K100M 50 70 80
PVP K 90 48 48 48
MCC 71 71 61
NaHCO3 40 40 40
Magnesium Stearate 8 8 8
Talc 8 8 8
    
                                             Total tablet weight: 850mg
4.2.5.2    Evaluation  of  Single  Unit  Floating  Matrix  Tablets  of  Amoxycillin
Trihydrate
 Weight variation
 Thickness
 Hardness
 Friability
 Floating time
 Floating lag time
 Amoxycillin trihydrate content
 In vitro amoxycillin trihydrate release
Weight Variation test
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Twenty  tablets  were  taken  and  their  weight  was  determined  individually  and
collectively  on  a  digital  weighing  balance.  The  average  weight  of  one  tablet  was
determined from the collective weight. The weight variation test would be a satisfactory
method of determining the drug content uniformity. The percent deviation was calculated
using the following formula. 
   % Deviation = (Individual weight – Average weight / Average weight) × 100
          Table 10: Pharmacopoeial specifications for tablet weight variation 
Average weight of tablets
(mg)  (IP)
Average  weight  of  tablets
(mg)  (USP)
Maximum percentage
difference allowed
         Less than 80
80-250
         More than 250
Less than 130 
130-324
More than 324
10
7.5
5
Thickness test 
The thickness in millimeters (mm) was measured individually for 10 pre-weighed tablets
by using a Vernier Callipers. The average thickness and standard deviation were reported.
Hardness test 
Dept. of pharmaceutics                                 68                                 J.K.K.M.M.R.F college of pharmacy
                                                                                  
Chapter04                                                                                       Materials and methods
Hardness of tablet is defined as the force applied across the diameter of the tablet in order
to break the tablet. The resistance of the tablet to chipping, abrasion or breakage under
conditions of storage, transportation and handling before usage depends on its hardness.
For each formulation, the hardness of 10 tablets was determined using Pfizer hardness
tester and the average was calculated and presented with standard deviation. 
Friability test
 Twenty (20) tablets were selected from each batch and weighed. Each group of
tablets was rotated at 25 rpm for 4 minutes (100 rotations) in the Roche friabilator. The
tablets were then dusted and re-weighed to determine the loss in weight.  Loss  in the
weight of tablet is the measure of friability and is expressed in percentage as:
      % Friability = [(W1 – W2) / W1] × 100 
Where        W1 = Initial weight of 20 tablets
                  W2 = Weight of the 20 tablets after testing
In vitro buoyancy studies  
The in vitro buoyancy was determined by floating lag time, as per the method described
by  Rosa  et  al.  The  tablets  were  placed  in  a  beaker  containing  100  mL  of  0.1N
hydrochloric acid. The time required for the tablet to rise to the surface and float was
determined  as  floating  lag  time.  The  duration  of  time  for  which  the  dosage  form
constantly remained on the surface of medium was determined as the total floating time.
Determination of Drug Content
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Twenty tablets were taken, powdered and the powder equivalent to one dose each was
transferred to a 100 mL volumetric flask and 0.1N HCl was added. The volume was then
made up to the mark with 0.1N HCl.  The solution was filtered and diluted suitably and
amoxycillin  trihydrate  content  in  the  samples  was  estimated  using  UV-  Visible
spectrophotometer at λmax of 272 nm.
In vitro Drug Release Studies
The in vitro amoxycillin trihydrate release study was performed for the single unit tablets
using USP Type II dissolution apparatus under the following conditions.
Dissolution test parameters
Medium : 900mL of 01.N HCl
Rotation speed : 50 rpm
Temperature : 37±0.5ºC
Sampling Volume : 5mL
Sampling Time : 0.5, 1, 2, 4, 6, 8, 10, 12 hours
At  predetermined  time intervals samples  (5 mL) were collected and replenished with
same volume of  fresh media.  The amoxycillin  trihydrate  content  in  the  samples  was
estimated using UV- Visible spectrophotometer at λmax of 272 nm.
4.2.6    KINETIC MODEL FITTING
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            An appropriate drug release test is required to characterize the drug
product  and  ensure  batch  to  batch  reproducibility  and  consistent
pharmacological/biological activity and to evaluate scale up and post approval changes
such as manufacturing site changes, component and composition changes. The release of
drug  from  a  sustained  release  formulation  is  controlled  by  various  factors  through
different mechanism such as diffusion, erosion or osmosis. Several mathematical models
are  proposed by many researchers  to  describe  the  drug  release  profiles  from various
systems. In order to characterize the kinetics of drug release from dosage forms several
model  dependent  methods  are  reported  by various  researchers.  The  model  dependent
methods all rely upon a curve fitting procedure. Different mathematical functions have
been used to model the observed data. Both the linear and non-linear models are being
used in practice for dissolution modelling. Linear models include Zero order, Higuchi,
Hixon - Crowell, Quadratic and Polynomials, where as the nonlinear models include First
order, Weibull, KorsMeyer - Peppas, Logistic etc.
There  are  several  linear  and  non-linear  kinetic  models  to  describe  release
mechanisms and to compare test and Reference dissolution profiles are as follows:
 Zero order kinetics
 First order kinetics
 Korsmeyer-Peppas model
 Higuchi model
A. Zero order kinetics.
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Drug dissolution from pharmaceutical dosage forms that do not disaggregate and
release  the  drug  slowly  (assuming  that  area  does  not  change  and  no  equilibrium
conditions are obtained) can be represented by the following equation:
W0 – Wt = K0t
 Where, W0 is the initial amount of drug in the pharmaceutical dosage form, Wt  is
the amount of drug in the pharmaceutical dosage form at time t and k is proportionality
constant. 
Dividing this equation by W0 and simplifying: 
ft = k0t
Where ft = 1 – (Wt / W0 ) and ft represents the fraction of drug dissolved in time t
and k0 the apparent dissolution rate constant or zero order release constant in this way, a
graphic  of  the  drug-dissolved  fraction  versus  time  will  be  linear  if  the  previously
established  conditions  were  fulfilled.  In  this  way  a  graphical  relationship  between  ft
versus time is established to get the Zero order constant from the slope. This relation can
be  used  to  describe  the  drug  dissolution  of  several  types  of  modified  release
pharmaceutical  dosage forms, as in the case of transdermal systems as well as matrix
tablets with low soluble drugs, coated forms, osmotic systems, etc. The pharmaceutical
dosage forms following this profile release the same amount of drug by unit of time and it
is  the ideal  method of  drug release  in  order  to  achieve  a  pharmacological  prolonged
action.
B. First order kinetics
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This  type  of  model  to  analyze  drug  dissolution  study  was  first  proposed  by
Gibaldi and Feldman and later by Wagner. The relation expressing this model:
Log Qt = Log Q0 - K1t/2.303
Where Qt is the amount of drug released in time t, Q0 is initial amount of drug in
the  solution  and  K1 is  the  first  order  release  rate  constant.  In  this  way  a  graphical
relationship is established between log percent drug remaining versus time to get the First
order  constant  from  the  slope.  The  pharmaceutical  dosage  forms  following  this
dissolution  profile,  such  as  those  containing  water-soluble  drugs  in  porous  matrices
release the drug in a way that is  proportional  to the amount of drug remaining in its
interior, in such a way, that the amount of drug released by unit of time diminishes.
C. Korsmeyer  Peppas  model:  Korsmeyer  et  al.,  (1983)  developed  a  simple  semi
empirical model, relating exponentially the drug release to the elapsed time (t).
Qt/Qα = Kktn
Where Kk is a constant incorporating structural and geometric characteristic of the drug
dosage form and n is the release exponent, indicative of the drug release mechanism. For
matrix tablets, an n value of ~0.5 indicates diffusion – controlled mechanism while an n
value of ~1.0 indicates erosion. Hariharan et al., 1997 a suggested that if the value of n is
0.5, it indicates Fickian transport, a value of 0.5 and 1.0 non-Fickian transport, and the
values  close to  1.0 indicate  that  the system is releasing drug in  a  zero-order  manner
regardless of the actual mechanism of release (Table 11).
    Table 11: Drug transport mechanism at various release exponent (n) values
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Release exponent (n) Drug transport mechanism Rate as a function of time
0.5 Fickian diffusion t-0.5
0.5<n<1.0 Anomalous  transport  (non-
fickian)
tn-1
1.0 Case-II transport Zero-order release
Higher than 1.0 Super Case-II transport tn-1
This  type  of  analysis  of  release  behaviour  is  valuable  to  the  formulator  for
comparative purposes  (Hariharan  et  al.,  1997).  The release  exponent  can be obtained
from the slope and the Constant (Kk) obtained from the intercept of the graphical relation
between logarithmic versions of left side of the equation versus log t.
D. Higuchi Model:
Qt = KHt1/2
Where Qt = the amount of drug released at time t and 
            KH = the Higuchi release rate;
This is the most widely used model to describe drug release from pharmaceutical
matrices.  A linear  relationship between the square root of time and the concentration
indicates that the drug release follows strictly Fickian diffusion.
For purpose of data treatment, the above equation is usually reduced to:
Q = Kt1/2
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Therefore a plot of amount of drug released versus the square root of time should
be linear, if drug release from the matrix is diffusion controlled. Alternatively, the drug
release rate is proportional  to the reciprocal  of the square root of time. An important
advantage of the above equation is its simplicity. 
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RESULTS AND DISCUSSIONS
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 5.RESULTS AND DISCUSSION
5.1 CALIBRATION CURVE OF AMOXYCILLIN TRIHYDRATE IN 0.1N HCl
An UV- Visible Spectrophotometric method was used for estimation of AMT. A solution
of AMT (10 µg/mL) was scanned in the wavelength range of 200-300 nm and found to
have maximum absorption (λmax) at 272 nm. 
Standard stock solutions of pure drug containing 100mg of AMT/100mL were prepared
in 10mL of methanol and making up the volume with 0.1N HCl solution. The working
standard  solutions  were  obtained by dilution of  the stock  solution in  0.1N HCl.  The
standard  curve  (Figure  10)  for  AMT was  prepared  in  the  concentration  range  of  0-
350µg/mL at the selected wavelength of 272nm. Their absorptivity values were used to
determine the linearity (Table 13). Solutions were scanned and Beer Lamberts law limit
was obeyed in concentration range of 0-350µg/mL.
                         Table 13: Calibration curve of AMT in 0.1N HCl at λmax 272 nm
S.NO Concentrations(µg/mL) Absorbance
1 0 0
2 10 0.032
3 50 0.145
4 100 0.284
5 150 0.428
6 200 0.563
7
300
0.828
8 350 0.964
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                         Figure 10: Standard Graph of AMT in 0.1N HCl
5.2 SOLUBILITY OF AMOXYCILLIN TRIHYDRATE
The solubility of AMT in 0.1N HCl was carried out. AMT is highly soluble in 0.1
N HCl, having quantitative solubility 139.1 mg/mL. It  shows pH dependent solubility,
highly soluble in acidic pH but poorly soluble in alkaline pH (as represented in Table 14).
              Table 14: Solubility study data of AMT
Medium Solubility (mg/mL)
0.1N HCl 139.1
6.8 pH phosphate buffer 4.7
Water 3.9
5.3 DRUG-EXCIPIENT COMPATIBILITY STUDIES
5.3.1 Fourier Transform Infrared (FT-IR) Spectroscopy
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The thermal behavior of pure drug and the respective excipients and the binary mixture of
drug and excipients are compared in the FT-IR thermograms.
The infrared (FT-IR) spectra were obtained in  KBr pellet method using a perkinelmer
FT-IR spectrometer spectrum from 4000 to 400 cm-1.
 Typical  FT-IR  spectra  of  pure  Amoxycillin  trihydrate  (Figure  11)  showed
absorption at the following wave number in cm-1  1775.23, 1686.51, 1578.29, 1519.61 &
1397.06.
Typical FT-IR spectra of pure xanthan gum (Figure 12) showed absorption at the
following wave number in cm-1 3448.04, 2924.54, 1718.20, 1654.20 & 1056.19.
Typical FT-IR spectra of pure HPMC K4M (Figure 13) showed absorption at the
following wave number in cm-1 3568.14, 2926.44, 1685.55, 1654.24, 1560.09, 1458.33 &
1064.45.
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Figure 11: FTIR spectrum of Amoxycillin trihydrate
Figure 12: FTIR spectrum of xanthan gum
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Figure 13: FTIR spectrum of Pure HPMC K4 M
The Figure 14 shows characteristics bands of Amoxycillin trihydrate which were well
retained  in the IR  spectrum of  Amoxycillin  trihydrate-  xanthan gum- HPMC K100M
mixture without any new bands, indicating that there was no change in the structure of
drug.  On  the  basis  of  above  report,  it  was  concluded  that  Amoxycillin  trihydrate  is
compatible with xanthan gum and HPMC K100M.
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Figure 14: FTIR spectrum of Amoxycillin trihydrate with Xanthan gum and HPMC
K100M
Characteristics bands of Amoxycillin trihydrate were well retained in the IR spectrum of
Amoxycillin trihydrate- HPMC K4M and all other excipients in formulation without any
new bands, indicating that there was no chemical incompatibility between Amoxycillin
trihydrate - HPMC K15- all other excipients in formulation is showed in the Figure 15.
On the basis of above results it was concluded that Amoxycillin trihydrate is compatible
with HPMC K4M and all other excipients in formulation.
Figure  15:  FTIR spectrum of  Amoxycillin  trihydrate  with  HPMC K4M and all
other excipients in formulation
FTIR were used to  investigate the compatibility between  Amoxycillin trihydrate with
excipients.  The  results  demonstrate  that  there  is  no  interaction  between  drug  and
excipients  (HPMC  K4M,  HPMC  K100M  and  Xanthan  gum).  Hence  Amoxycillin
trihydrate with these excipients could be used to formulate the floating tablets.
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5.4 PHYSICAL PROPERTIES OF PREPARED POWDER BLENDS
Various properties of granules such as Carr’s Index, Hausner’s Ratio,% Compressibility
index and angle of repose were determined and the results are shown in the table 15.
Table 15: Physical properties of powder blends of single unit tablet formulations 
Formulations % CI Angle of repose Hausner ratio
F1 15.7 29.4o 1.18
F2 12.4 28.5o 1.14
F3 11.2 29.4o 1.13
F4 15.7 29.4o 1.02
F5 12.4 28.5o 1.14
F6 11.2 29.4o 1.13
F7 13.6 28.4o 1.02
F8 12.5 26.9o 1.16
F9 14.6 27.5o 1.15
F10 12.6 27.1o 1.17
F11 15.7 29.4o 1.02
F12 12.4 28.5o 1.14
F13 11.2 29.4o 1.13
Carr’s index of the granules ranged from 11.2 to 15.7 showing the granules are
freely  flowing  (C.I  =  12-16  indicating  good  flowing  granules).  Hausner’s  ratio  of
granules  was  found  to  be in  the range  of  1.02 to  1.18 (H.R.  =  0-1.2  indicating free
flowing property). The angle of repose of granules of all the formulations was found to be
≤ 30°, hence are freely flowing. The results of the physical tests of many of the blends
were in the limits and comply with the standards.
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5.5  EVALUATION  OF  PHYSICAL  PARAMETERS  OF  SINGLE  UNIT
FLOATING TABLETS OF AMT
All the prepared formulations were tested for Physical parameters like Hardness,
thickness, Weight Variation, Friability and found to be within the Pharmacopoeias limits.
The results  of the tests  were tabulated.  The drug content  of  all  the formulations was
determined and was found to be within the permissible limit. This study indicated that all
the prepared formulations were good.
Table 16: Physical parameters of single unit floating matrix tablets of AMT
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 The results of the physical tests of the formulations were within the limits and
comply with the standards. The weights of the tablets ranged from 847.2mg to 852.2mg;
the weights being with ±5% of the average weight. The thickness was found to be in the
range 6.506mm to 6.86mm. Hardness of the tablets was in the range of 5.9 to 6.8kg/cm2
and friability was in the range 0.22 to 0.37%, indicating that the tablets are hard enough
to withstand the external mechanical stresses. The drug content on an average was found
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Formulation
code
Weight
variation (mg)
Hardness
(kg/cm2)
Thickness
(mm)
Friability
(%)
Assay
(%)
F1 850.38±3.84 6.8±0.5 6.84±0.05 0.22 99.65
F2 849.52±2.87 5.9±0.2 6.76±0.06 0.37 98.65
F3 852.23±2.73 6.8±0.5 6.86±0.03 0.23 98.45
F4 848.6±2.13 6.8±0.4 6.76±0.04 0.29 99.64
F5 850.19±3.48 6.8±0.5 6.63±0.06 0.23 98.45
F6 849.71±2.3 5.9±0.2 6.65 ±0.06 0.29 99.64
F7 847.2±1.19 6.8±0.5 6.68±0.05 0.37 98.12
F8 849.46±2.27 6.5±0.3 6.55±0.25 0.23 99.72
F9 850.67±3.84 6.8±0.5 6.506±0.04 0.29 98.45
F10 848.38±3.84 6.7±0.2 6.62±0.07 0.37 99.64
F11 848.6±2.13 6.8±0.4 6.76±0.04 0.29 99.64
F12 850.19±3.48 6.8±0.5 6.63±0.06 0.23 98.45
F13 849.71±2.3 5.9±0.2 6.65 ±0.06 0.29 99.64
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to  be 99.72%. All  these parameters  were  within acceptable  limits.  The results  of  the
physical  tests  of  many  of  the  formulations  were  in  the  limits  and  comply  with  the
standards.
5.6 FLOATING PROPERTIES OF SINGLE UNIT TABLETS OF AMT
All the formulations were tested for floating properties like floating lag time and total
floating time. All the batches showed good in vitro buoyancy. The results of the in vitro
buoyancy study were shown in Table17.         
                  Table 17: Floating properties of single unit matrix tablets
Formulation
code
Floating Lag time
(sec)
Total floating
time (hrs)
F1 89 >12
F2 99 >12
F3 101 >12
F4 98 >12
F5 94 >12
F6 79 >12
F7 84 >12
F8 89 >12
F9 94 >12
F10 79 >12
F11 84 >12
F12 89 >12
F13 101 >12
 5.7 IN – VITRO DRUG RELEASE PROFILES
The dissolution conditions used for  studying  the drug release  from the matrix
tablets of AMT were:
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Apparatus : USP Type 2 (paddle)
           Agitation speed (rpm)  : 50
           Medium   : 0.1N HCl (pH 1.2), 900mL
           Temperature    : 37.0 ± 0.50C
            Time    : 0.5, 1, 2, 4, 6, 8, 10, and 12hr
            Wavelength    : 272nm.
                   5.7.1   SINGLE UNIT FLOATING MATRIX TABLETS
i) Release profiles of formulations containing HPMC K4M
      Table 18: Cumulative percentage drug release of formulations with HPMC K4M
Time points
(hrs)
F1 F2 F3
0 0 0 0
0.5 16.84±1.89 14.40±3.56 7.25±1.76
1 31.60±3.18 25.88±3.30 16.04±3.09
2 56.27±3.01 42.75±3.08 23.01±2.66
4 83.95±1.50 58.74±0.70 38.21±1.52
6 96.71±1.30 76.63±1.16 54.23±3.05
8 ---- 91.07±2.02 74.43±4.59
10 ---- 99.71±2.39 87.79±1.28
12 ---- ---- 98.33±2.70
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Figure 16: Cumulative % drug release of formulations containing HPMC K4M 
From the  above figure  it  can  be observed  that  the polymer  HPMC K4M has
sustaining effect on the release of drug from the floating matrix tablet. The percent of
drug release from formulations F1, F2 and F3 was 96.71% in 6hrs, 99.71% in 10hrs, and
98.3% in 12hrs respectively.  Formulation F1 was unable to sustain the drug release to
desired period of time (total drug was released within 6 hr).  Formulations F2 was failed
to release the drug within the desired time. The difference in the drug release profiles of
various formulations was due to the presence of different concentrations of polymer. All
these three formulations floated for 12 hrs. The cumulative percent drug release from
various formulations was presented in table 18. Formulation F3 was considered as best
formulation among all  the three  formulations  as it  showed good buoyancy properties
Dept. of pharmaceutics                             89                                   J.K.K.M.M.R.F college of pharmacy
                                                                                  
Chapter 05                                                                                         Results and discussion
(floating lag time: 101sec & floating time >12 hrs) and sustained the drug release for
desired period of time (12 hrs). 
ii) Release profiles of formulations containing HPMC K15M
         Table 19: Cumulative percentage drug release of formulations with HPMC
K15M
Time points
(hrs)
F4 F5 F6 F7
0 0 0 0 0
0.5 29.34±3.21 23.59±2.05 13.54±2.11 13.68±1.91
1 42.79±2.63 32.53±3.06 14.47±1.84 15.44±0.19
2 52.63±2.57 45.40±2.03 26.58±2.94 26.25±3.30
4 83.07±2.32 68.14±1.61 36.02±3.60 37.21±4.12
6 97.24±2.28 86.40±3.15 48.14±2.22 54.08±3.69
8 ---- 97.60±2.01 65.25±3.08 72.76±3.83
10 ---- ---- 76.02±3.45 85.90±3.44
12 ---- ---- 86.49±4.47 99.80±4.51
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     Figure 17: Cumulative % drug release of formulations containing HPMC K15M 
From the above figure it is evident that the polymer HPMC K15M has sustaining effect
on the release of drug from the floating matrix tablet. The percent of drug release from
formulations F4, F5, F6, and F7 was 97.24% in 6hrs, 97.60% in 8hrs, 86.49% and 99.8%
in 12hrs  respectively.  Formulation  F4  was unable to  sustain  the drug  release  desired
period of time (total drug was released within 6 hr). Formulations F5 and F6 were failed
to release the drug within the desired time. The difference in the drug release profiles of
various formulations was due to the presence of different concentrations of polymer. All
these four  formulations floated for  12 hrs.  The cumulative percent  drug release from
various formulations was represented in Table 19. Formulation F7 was considered as best
formulation  among all  the  four  formulations  as  it  showed  good  buoyancy  properties
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(floating lag time: 84 sec & floating time >12 hrs) and sustained the drug release for
desired period of time (12 hrs). 
iii) Release profiles of formulations containing HPMC K100M
    Table  20: Cumulative  percentage  drug  release  of  formulations  with  HPMC
K100M
Time points
(hrs)
F 8 F 9 F10
0 0 0 0
0.5 22.21±2.73 21.89±2.95 13.67±1.45
1 30.83±1.44 30.51±1.67 17.67±1.85
2 45.64±2.02 46.21±1.26 25.72±1.90
4 67.73±2.15 65.69±3.96 45.29±4.56
6 88.53±2.55 81.02±4.37 53.81±2.89
8 101.14±1.37 87.76±1.93 76.80±2.28
10 ---- 97.43±7.10 93.30±2.05
12 ---- ---- 100.46±1.84
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Figure 18: Cumulative % drug release of formulations containing HPMC K100M 
From the above figure it is evident that the polymer HPMC K100M has sustaining effect
on the release of drug from the floating matrix tablet. The percent of drug release from
formulations F8, F9 and F10 was 101.14% in 8hrs, 97.43% in 10hrs and 100.46% in
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12hrs respectively. Formulation F8 was unable to sustain the drug release desired period
of time (total drug was released within 8 hr). Formulations F9 was failed to release the
drug  within  the  desired  time.  The  difference  in  the  drug  release  profiles  of  various
formulations was due to the presence of different concentrations of polymer. All these
three formulations floated for 12 hrs. The cumulative percent drug release from various
formulations  was  represented  in  table  20.  Formulation  F10  was  considered  as  best
formulation among all  the three  formulations  as it  showed good buoyancy properties
(floating lag time: 79 sec & floating time >12 hrs) and sustained the drug release for
desired period of time (12 hrs). 
Table 21: Cumulative percentage drug release of formulations with combination of
xanthan gum and HPMC K100M
Time points
(hrs)
Cumulative % drug released
F11 F12 F13
0 0 0 0
0.5 28.04±2.59 17.87±2.032 6.045±1.48
1 36.17±2.24 25.58±2.70 17.82±1.04
2 48.16±3.49 46.60±2.80 24.02±1.37
3 60.73±1.91 57.91±2.57 39.73±0.92
4 75.45±2.79 62.52±1.41 52.24±1.66
6 87.50±1.92 76.93±1.00 67.10±1.74
8 101.45±1.99 90.80±1.54 79.50±0.92
10 ---- 103.56±1.98 87.14±1.96
12 ---- ---- 100.08±3.73
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Figure 19: Cumulative percentage drug release of formulations with combination of
xanthan gum and HPMC K100M
From the above figure it can be observed that the polymers having xanthan gum
and HPMC K100M sustaining effect  on the release of  drug from the floating matrix
tablet. The percent of drug release from formulations F11, F12 and F13 was 101.45% in
8hrs, 103.56% in 10hrs and 100.08% in 12hrs respectively. Formulation F11 was unable
to sustain the drug release desired period of time (total drug was released within 8 hr).
Formulations F12  failed to release the drug within the desired time. The difference in the
drug  release  profiles  of  various  formulations  was  due  to  the  presence  of  different
concentrations  of  polymers.  All  these  three  formulations  floated  for  12  hrs.  The
cumulative percent drug release from various formulations was represented in table 21.
Formulation F13 was considered as best formulation among all the three formulations as
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it showed good buoyancy properties (floating lag time: 101sec & floating time >12 hrs)
and sustained the drug release for desired period of time (12 hrs). 
5.8 MATHEMATICAL MODELING OF DISSOLUTION PROFILES 
Table 22: Regression coefficient (R2) values of single unit floating matrix tablets for
different kinetic models 
Formulation
R2 value
n valueZero-
order
First
order
Higuchi Korsmeyer- Peppas
F1 0.9300 0.9800 0.9803 0.9776 0.620
F2 0.9400 0.8100 0.9939 0.9937 0.580
F3 0.9920 0.8750 0.9590 0.9890 0.763
F4 0.9060 0.9588 0.9947 0.9760 0.480
F5 0.9370 0.9370 0.9981 0.9980 0.540
F6 0.9840 0.9730 0.9690 0.9890 0.700
F7 0.9918 0.9470 0.9570 0.9911 0.746
F8 0.9500 0.9740 0.9950 0.9990 0.578
F9 0.9080 0.9490 0.9960 0.9930 0.502
F10 0.9850 0.8853 0.9630 0.9890 0.721
F11 0.9114 0.9876 0.9963 0.9926 0.508
F12 0.9251 0.9782 0.9936 0.9775 0.572
F13 0.9599 0.9946 0.9766 0.9815 0.726
 Drug release kinetics of formulations F1, F2 and F3 containing a HPMC K4M at
a Drug:Polymer ratio of 1:0.17, 1:0.22 and 1:0.26 are shown in the table 22. From the
correlation coefficient values it was evidenced that formulations F1 and F2 released drug
by Higuchi model. The optimized formulation F3 released drug by Zero-order release
complying with higher correlation coefficient values of  0.9920 for Zero-order equation.
The drug release mechanism for all the three formulations was governed by non-fickian
diffusion which was confirmed by their release exponent (n) values.
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Drug release  kinetics  of  formulations  F4,  F5,  F6  and F7  containing a  HPMC
K15M at a Drug:Polymer ratio of 1:0.13, 1:0.17, 1:0.26 and 1:0.23 are shown in the table
22. From the correlation coefficient values it was evidenced that formulations F4 and F5
released drug by Higuchi model.  Formulation F6 released drug by Korsmeyer-Peppas
model.  The  optimized formulation F7 released drug by Zero-order  release  complying
with higher correlation coefficient values of  0.9918  for Zero-order equation. The drug
release mechanism for all the four formulations was governed by non-fickian diffusion
which was confirmed by their release exponent (n) values.
Drug release kinetics of formulations F8, F9 and F10 containing a HPMC K100M
at a Drug:Polymer ratio of 1:0.09, 1:0.13 and 1:0.17 are shown in the table 22. From the
correlation coefficient  values it  was evidenced that  formulations F8 and F10 released
drug by Korsmeyer-Peppas model. The formulation F9 released drug by Higuchi model.
The drug release mechanism for all the three formulations was governed by non-fickian
diffusion which was confirmed by their release exponent (n) values.
Drug release kinetics of formulations F11, F12 and F13 containing a Xanthan gum and
HPMC K100M at a Drug: xanthan gum: HPMC K100M ratio of 1:0.09:0.09, 1:0.06:0.12
and 1:0.04:0.14 are shown in the table 22. From the correlation coefficient values it was
evidenced that formulations F11 and F12 released drug by Higuchi model. The optimized
formulation F13 released drug by First-order release complying with higher correlation
coefficient values of 0.9946 for First-order equation. The drug release mechanism for all
the three formulations was governed by non-fickian diffusion which was confirmed by
their release exponent (n) values.
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The formulation F13 showed high regression value of 0.9946 for  Higuchi  order  with
complete  drug  release  in  12  hrs  made it  to  be  selected  as  an  optimized  formulation
compared with other formulations.
5.9 STABILITY STUDIES:
5.9.1 Introduction:
Storage conditions recommended
General case
                 Table No. 23 Testing frequency for different storage conditions
Study Storage condition Minimum time period
covered by data at
submission
Long term* 250C + 20C/60% RH + 5% RH or
300C + 20C/65% RH + 5% RH
12 months
Intermediate** 300C + 20C/65% RH + 5% RH 6 months
Accelerated 400C + 20C/75% RH + 5% RH 6 months
* It is up to the applicant to decide whether long term stability studies are performed at
25 + 2oC/60% RH + 5% RH or 30 0C + 2oC/65% RH + 5% RH. 
**If 30oC + 2oC/65% RH + 5% RH is the long-term condition, there is no intermediate
condition. 
If  long-term studies  are  conducted at  25oC+ 2oC/60% RH + 5% RH and “significant
change” occurs at any time during 6 months’ testing at the accelerated storage condition,
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additional  testing  at  the  intermediate  storage  condition  should  be  conducted  and
evaluated against significant change criteria.
Stability Testing for Established Drug Substances
WHO has issued guidelines for stability testing of pharmaceutical products containing
well established drug substances in conventional dosage form. The stability of finished
pharmaceutical  products  depends  on  environmental  factors  and  on  product  related
factors. So stability considerations should be given, the highest priority in the design and
formulation of a product.  The shelf life should be established with due regard to the
climatic  zones.  To  ensure  both  patient  safety  and  the  rational  management  of  drug
supplies, it is important that the expiry date and storage conditions are properly indicated
on the label.
Accelerated stability testing
These are the studies designed to increase the rate of chemical degradation and physical
change of a drug by using exaggerated storage conditions as part of the formal stability
testing programme. The data thus obtained, in addition to those derived from real – time
stability  studies,  may  be  used  to  assess  longer  –  term  chemical  effects  under  non-
accelerated conditions and to evaluate the impact of short-term excursions outside the
label  storage  conditions,  as  might  occur  during  shipping.  The  results  of  accelerated
testing studies are not always predictive of physical changes. These are also known as
stress testing studies.
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Expiry date
The date given on the individual container of a drug product up to and including which
the product is expected to remain within specifications if stored correctly. It is established
for each batch by adding the shelf-life period to the date of manufacture.
Mean Kinetic Temperature
The single test temperature for a drug product corresponding to the effects on chemical
reaction kinetics of a given temperature – time distribution. A mean kinetic temperature
is calculated for each of the four world climatic zones according to the formula developed
by  a  scientist  known  as  Hayanes.  It  is  normally  higher  than  the  arithmetic  mean
temperature.
Real time (Long term) stability studies
Experiments  on  the  physical,  chemical,  biological,  biopharmaceutical  and
microbiological characteristics of a drug, during and beyond the expected shelf life and
storage periods of samples under the storage conditions expected in the intended market.
The results are used to establish the shelf life, to confirm the projected shelf life and to
recommend storage conditions.
Stability tests
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A series  of  tests  designed  to  obtain  information  on the stability  of  a  pharmaceutical
product in order to define its shelf-life and utilization period under specified packging
and storage conditions.
The following table gives the main objectives and uses the different types of stability
testing
                                  Table No. 24 Objectives of Stability Testing
Objective Type of study Use
To select adequate (from the viewpoint
of stability) formulations and container-
closure systems
Accelerated
Development of the
product
To determine shelf-life and storage
conditions
Accelerated and
real-time
Development of the
product and of the
registration dossier
To substantiate the claimed shelf-life Real-time Registration dossier
To verify that no changes have been
introduced in the formulation or
manufacturing process that can
adversely affect the stability of the
product
Accelerated and
real- time
Quality assurance in
general, including
quality control.
Test Samples
For established products the following schedule is suggested by WHO:
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• One batch every other year  for formulations considered to be stable, otherwise
one batch per year.
• One batch every 3 – 5 years for formulations for which the stability profile has
been established, unless a major change has been made, e.g. in the formulation or
the method of manufacture.
5.9.2 Experimental work
The  Amoxycillin  trihydrate  Tablets  of  F13  was  packed  in  HDPE bottles  with  Child
Resistance Caps (CRC) and induction sealed. These bottles were charged for stability
study at 400C / 75% RH.
Sampling time points: Initial, 1month, 2months
Evaluation parameters: Appearance and physical parameters of tablets, Assay and % drug
dissolved.
After one month
           Table No. 25 Physical evaluation for stability studies of optimized formulations
Initial 400C / 75% RH
Colour white white
Thickness (mm) 6.65mm 6.64 mm
Hardness (kp) 5.9-6.0 5.8-5.9
Weight (mg) 849.71±2.3 849.61±1.9
Assay 99.64% 99.40%
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Table No. 26  Percentage Cumulative release of stability studies of optimized formulation
(F13) at 400C / 75% RH for 1 month
Time
(hours)
Cumulative % drug release for 1 month
Intial 400C / 75% RH
0 0 0
0.5 6.045 6.045
1 17.82 17.79
2 24.02 24
3 39.73 39.69
4 52.24 52.19
6 67.10 66.90
8 79.50 78.94
10 87.14 86.99
12 100.08 99.97
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             Fig No.20 Dissolution profiles of 1 months stability samples at 400C / 75% RH
After two month
            Table No. 27  Physical evaluation for stability studies of optimized formulations
Initial 400C / 75% RH
Colour White White
Surface Smooth Smooth
Thickness (mm) 6.65 mm 6.60 mm
Hardness (kp) 5.9-6.0 5.6-5.8
Wight (mg) 849.71±2.3 849±1.0
Assay 99.64% 99.04%
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Table No. 28  Percentage Cumulative release of stability studies of optimized formulation
(F13) at 400C / 75% RH for two month
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Time
(hours)
Cumulative % drug release for 2 month
Intial 400C / 75% RH
0 0 0
0.5 6.045 6.045
1 17.82 17.60
2 24.02 23.81
3 39.73 39.03
4 52.24 52
6 67.10 66
8 79.50 78.10
10 87.14 86.09
12 100.08 99.04
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                 Fig No.21 Dissolution profiles of 2 months stability samples at 400C / 75% RH
Optimized formulation (F13) was kept for stability studies, and observed that assay after
1st, 2nd month was complies with optimized formulation. Dissolution profile of stability
samples  after  1st,  2nd months  were  compared  with  formulation  (F13).There  is  no
significant change in In vitro release profile in both conditions when compared with F13.
It shows that it is stable formulation.
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      SUMMARY AND CONCLUSION
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6. SUMMARY AND CONCLUSION
SUMMARY
In the present work attemps have been made to formulate floating tablets of 
Amoxicillin trihydrate with HPMC K4M, HPMC K15M, HPMC K100M, and Xanthan 
gum by direct compression method by taking single polymer in the formulation. 
Amoxicillintrihydrate has shown high solubility in 0.1N HCl. Therefore it was 
considered as a good candidate for gastro retentive dosage form
The development of gastro retentive floating drug delivery system of Amoxicillin 
trihydrate, to increase gastric residence time and thereby its therapeutic efficacy against 
H.Pylori in single unit floating matrix tablets  with different natural and synthetic 
polymers meets all the ideal characteristics to formulate in the form of floating tablets.
Based on the studies of the APIs organoleptic properties were complied with the BP and 
IP specifications. Physical properties such as bulk density and tapped density, angle of 
repose, carr’s index, hausners ratio were within official standards.
Systematic studies were conducted for the preparation of floating delivery systems of 
Amoxycillin trihydrate. FT-IR studies showed no incompatibility between drug, polymer 
and various excipients used in the formulations.
Formulated tablets gave satisfactory results for various evaluation parameters like tablet 
dimensions, hardness, weight variation, friability, content uniformity, in vitro buoyancy 
properties and in vitro drug release.
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CONCLUSION
The present study shows that  Amoxicillin trihydrate  can be made into floating tablet
dosage form by direct compression technique.
 Amoxicillin  trihydrate  floating  tablets  with  HPMC  K4M,  HPMC  K15M,  HPMC
K100M, and Xanthan gum by taking single polymer in the formulations in which F3, F7,
F10 and F13 gave better controlled drug release and floating properties in comparison to
the other formulations.From the correlation coefficient values, the drug release from the
optimized formulations F3 and F7 followed Zero-order pattern, F10 and F13 followed
Higuchi  and  First-order  pattern  respectively.  The  transport  of  drug  from  all  the
formulations was governed by Non-Fickian mechanism which was confirmed by release
exponent ‘n’ values of Koresmeyer Peppas equations. 
 Dissolution  profile  of  stability  samples  after  1st,  2nd months  were  compared  with
formulation  (F13).There  is  no  significant  change  in  In  vitro  release  profile  in  both
conditions when compared with F13. It shows that it is stable formulation
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